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Despite efforts to reduce the malaria burden in high transmission areas like 
Western Kenya, malaria has persisted, making it important to identify remaining malaria 
reservoirs. Asymptomatic infections could be sustaining transmission, but their role as a 
reservoir has not been quantified. Furthermore, the relationship between asymptomatic 
malaria and future symptomatic infection is poorly understood. 
Using a 29-month cohort of 268 participants residing in Western Kenya, this 
dissertation aimed to (1A) investigate the hazard of symptomatic P. falciparum when 
exposed to asymptomatic malaria versus no infection; (1B) establish the odds of 
symptomatic infection when exposed to new compared to previously acquired 
infections; and (2) estimate the relative contributions of asymptomatic and symptomatic 
human infections to successful onward mosquito transmission events. 
 With a frailty Cox model, aim 1A found that infection with asymptomatic malaria 
compared to being uninfected greatly increased the short-term, 1-month hazard of 
symptomatic malaria [hazard ratio: 2.61, 95% CI: 2.05 to 3.33], regardless of parasite 
density or participant age, but the association weakened as the follow-up period was 
expanded. Next, using amplicon deep sequencing to determine genetically distinct 
malaria infections (haplotypes) acquired over time, aim 1B identified that, compared to 
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infections with only recurrent haplotypes, incident infections with only new haplotypes 
had higher odds of symptomatic malaria [odds ratio (OR): 3.24, 95% CI: 1.20 to 8.78] 
but infections with both new and recurrent haplotypes had comparable odds of 
symptomatic malaria [OR: 0.64, 95% CI: 0.15 to 2.65]. Using amplicon deep sequencing 
of human and mosquito samples as well as probabilistic modelling, aim 2 observed that, 
compared with symptomatic infections, asymptomatic infections more than doubled the 
odds of transmission to a mosquito [OR 2.66, 95% CI: 2.05 to 3.47] and were the likely 
source of 94.6% (95% CI: 93.1 to 95.8%) of mosquito infections.  
These findings indicate that asymptomatic infections increase the 1-month 
hazard of symptomatic malaria, are more common in incident infections with previously 
seen haplotypes, and are major contributors to mosquito infections. Taken together, this 
research provides a rationale to include asymptomatic infections as a part of malaria 
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CHAPTER I: SPECIFIC AIMS 
 
 
Over 70% of Kenya’s population lives in a high transmission area of Plasmodium 
falciparum.1,2 Prevalence is highest in Western Kenya where parasites are found in up 
to 80% of residents.3 Malaria reduction efforts are ongoing;4,5 but, high P. falciparum 
prevalence persists, highlighting the need to identify the region’s malaria reservoirs.6,7  
Asymptomatic malaria infections could be reservoirs for sustained malaria 
transmission and are prevalent in Western Kenya.6,8,9 Previous work has longitudinally 
assessed asymptomatic malaria incidence, intra-host immunology, parasite density, and 
mosquito biting exposure;10–13 but, the amount asymptomatically-infected humans 
transmit malaria to mosquitoes remains unresolved. It is also unclear whether 
asymptomatic infections impact the severity of subsequent symptomatic infections 
within the same host, with asymptomatic infections increasing the risk of future 
symptomatic infections in some studies and decreasing the risk in others.14–23 
Understanding the transmission dynamics and disease progression of asymptomatic 
malaria is important for understanding its reservoir role.  
Our overall objective was to explore the natural history of asymptomatic P. 
falciparum infection and its relationship to future symptomatic infection and transmission 
to mosquitoes. Our central hypothesis was that preceding, new asymptomatic infections 
would increase the short-term risk of future symptomatic infection and be a large source 
of malaria transmission compared to symptomatic malaria. To investigate this 
hypothesis, we used a longitudinal cohort in Webuye, Western Kenya, a hyperendemic 
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malaria site. We collected blood samples from human participants asymptomatic 
(monthly) and symptomatic (as suspected) for malaria as well as mosquitoes from 
participant households (weekly). We aimed to: 
Aim 1A: Investigate the hazard of symptomatic P. falciparum when exposed 
to asymptomatic infections compared to no malaria infections. Asymptomatic 
infections had malaria parasites in blood samples and no malaria symptoms. 
Symptomatic infections had malaria parasites in blood samples and at least one malaria 
symptom (ex. fever, headache, nausea). We assessed the hazard of symptomatic P. 
falciparum infection in humans across the time-varying exposure (asymptomatic malaria 
infection vs. no malaria infection). We hypothesized that participants with asymptomatic 
infections during the study period would have a higher short-term hazard of future 
symptomatic infection compared to those that were uninfected. 
       Aim 1B: Establish the odds of symptomatic P. falciparum infection compared 
to asymptomatic infection when exposed to new infections compared to recurrent 
or persistent infections. Using only blood samples from humans with asymptomatic 
and symptomatic malaria, we performed amplicon deep sequencing of two polymorphic 
P. falciparum gene segments to create haplotypes (distinct sequences of a parasite 
gene target) that represented genetically-distinct malaria infections. We determined 
genetic relatedness of an individual’s infections by comparing haplotypes across 
infections. We analyzed the odds of symptomatic compared to asymptomatic malaria 
across infections with new versus recurrent or persistent haplotypes. We hypothesized 
we would observe greater odds of symptomatic infection compared to asymptomatic 
infection when a new haplotype was present in the infection. 
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Aim 2: Estimate the relative contributions of asymptomatic and 
symptomatic P. falciparum human infections to successful onward mosquito 
transmission events in a high transmission area. Using blood samples from (i) 
humans with asymptomatic and symptomatic malaria and (ii) female Anopheles 
mosquitoes from those participants’ households, we sequenced two parasite gene 
targets and counted the number of shared parasite haplotypes between a human 
infection and mosquito found in the human’s household. A probability of human-to-
mosquito transmission value was calculated based on the time, distance, and 
haplotypes shared between human and mosquito samples; this value was compared 
across humans with asymptomatic to symptomatic infections. We hypothesized that 
asymptomatic humans compared to symptomatic humans would have a higher 
probability of malaria transmission to mosquitoes. 
Using data collected with an established malaria research team in Webuye,24–33 
we determined if asymptomatic infections were providing a protective effect against 
symptomatic infection or becoming symptomatic themselves over time. We also 
established if asymptomatic humans highly contributed to mosquito infection and 
onward transmission. Findings inform the utility of active test and treat strategies for 





CHAPTER II: BACKGROUND 
 
P. falciparum Overview and Global Burden 
Malaria is a large global health problem with over 200 million cases reported 
annually.34 Most cases occur in sub-Saharan Africa, which is the focal area for 
transmission of the most deadly malaria species, Plasmodium falciparum.2,34 Over 70% 
of Kenya’s population lives in a high transmission area of P. falciparum, leading to a 
high number of malarial deaths.1 In fact, Kenya is one of 29 countries that contributed to 
95% of malarial deaths that occurred world-wide in 2019.34 In Kenya, the risk of malaria 
is highest in the Western region where P. falciparum parasite prevalence is greater than 
300 cases per 1000 population.1   
Many vector control and preventative therapy measures have been implemented 
in hyperendemic areas like Western Kenya. In sub-Saharan Africa, access to 
insecticide-treated bed nets increased from 5 to 68% from 2000 to 2019, and indoor 
residual spraying has remained a protective vector control strategy.34 In mainly West 
Africa, pregnant women and children have received prophylactic antimalarials through 
seasonal malaria chemoprevention programs.34 These preventative efforts are reducing 
malaria cases across Africa, but case reductions have plateaued since 2010,34,35 with 
efforts presumably having a smaller effect. Many regions are still experiencing a high 
number of malaria cases and, for some countries, increasing case counts. This malaria 
persistence could be due to intervention efforts not effectively reducing the malaria 
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reservoir, which describes individuals and infections that disproportionately contribute 
more to parasite transmission. As intervention efforts push regions toward elimination, it 
becomes increasingly important to identify these malaria reservoirs.  
P. falciparum Life Cycle 
Identification of reservoirs for malaria transmission requires knowledge of the 
disease’s life cycle. P. falciparum’s life cycle involves an asexual stage in humans 
where commitment to the sexual gametocyte stage occurs and a sexual replication 
stage in the vector, female Anopheles mosquitoes, where replication between male and 
female gametocytes occurs.36  
To assess human-to-mosquito malaria transmission, we followed the malaria 
parasite at different stages in its life cycle. For study participants, we captured asexual 
and sexual malaria parasites during the blood stage of infection using dried blood spots. 
The blood stage of the parasite life cycle is responsible for causing clinical symptom 
development in infected humans.37 For P. falciparum there is a hypothesized incubation 
period of 9 to 14 days between a person being bitten by a mosquito and the 
development of symptoms;38 however, this incubation period is not well supported with 
a study finding symptoms developed up to 12 weeks after the initial asymptomatic 
infection was recorded.16 In some case studies, untreated infections remained 
asymptomatic for 6 months to 13 years.39 Using the dried blood spots collected during 
the parasite’s blood stage in humans, we identified parasite haplotypes (distinct 
sequences of a gene target) as a measure of parasite genetic diversity. We detected 




When female Anopheles mosquitoes bite a malaria-infected person, they ingest 
malaria gametocytes. To follow gametocyte transmission to mosquitoes, we collected 
mosquitoes from participants’ households. Over an average of 9 to 18 days,37 ingested 
gametocytes sexually reproduce in the mosquitoes’ midgut to produce ookinetes and 
then oocysts that later burst to release sporozoites into the mosquitoes’ salivary glands. 
These sporozoites could then be transferred to another person via a mosquito bite.40,41 
Multiple genetically-distinct malaria parasites could reside in a mosquito’s salivary 
glands and mosquitoes could take multiple blood meals, leading to human infection with 
multiple malaria parasite haplotypes.42 We detected parasite haplotypes in female 
Anopheles mosquito abdomens and matched those to parasite haplotypes in humans to 
capture human-to-mosquito malaria transmission and quantify how asymptomatic and 
symptomatic infections in humans act as reservoirs for transmission.  
Asymptomatic Malaria and Mosquito Transmission  
Asymptomatic malaria has been hypothesized to be a significant source, or 
reservoir, of sustained malaria transmission.9,36,43–46 Asymptomatic malaria infections 
could be pre-symptomatic infections that have not yet progressed to symptomatic 
malaria or infections that never progress to symptomatic malaria due to a partial, anti-
disease immune response.47 Twenty-four percent of sub-Saharan Africa's population is 
estimated to harbor an asymptomatic infection,35 and asymptomatic infection 
prevalence correlates with transmission intensity; high transmission areas have higher 
asymptomatic infection prevalence.48–51 In high transmission regions, asymptomatic 
malaria also likely occurs at a higher prevalence than symptomatic malaria.35,52–54 This 
is seen in Western Kenya where asymptomatic infections were found in 38 to 50% of 
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school-aged children living in hyperendemic areas.6,8  
High prevalence of asymptomatic malaria is an enormous issue because the 
same asymptomatic infection could persist in individuals for years.39 This long infection 
duration allows many opportunities for a mosquito to bite an infected individual and 
transmit malaria to someone else. Many factors influence the likelihood of this route of 
malaria transmission, such as mosquito gametocyte ingestion, malaria parasite density 
(asexual and sexual), human host factors, multiclonal infections, and immunological 
responses.55–58   
The frequency of P. falciparum transmission from asymptomatic or symptomatic 
humans to mosquitoes has been measured using cross-sectional and experimental 
studies, but results have been conflicting.59–63 For example, an experimental study in 
Western Kenya assessed membrane feeding of Anopheles gambiae mosquitoes on 
asymptomatic and symptomatic infected humans and found that asymptomatic 
infections passed more gametocytes to mosquitoes than symptomatic infections.61 This 
was observed in the higher oocyst rate in the mosquitoes that fed on asymptomatic 
humans (12%) compared to those that fed on symptomatic humans (0.6%).61 In 
contrast, a study in Brazil discovered that parasites from symptomatic infections were 
transmitted to mosquitoes more often than those from asymptomatic infections, but 
asymptomatic infections were more prevalent and persisted for a longer duration.59 It is 
important to note that these studies had small sample sizes, participants who recently 
took antimalarial treatment or contrived mosquito feeding systems, making results not 
easily generalizable. Modeling studies have tried to estimate the amount of human-to-
malaria transmission that could occur,64,65 suggesting that submicroscopic individuals 
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(with parasite densities below the threshold for microscopy detection) contribute to 20 to 
50% of human-to-mosquito malaria transmissions in low-transmission settings65 and 
>50% of transmissions in high-transmission settings.66,67 Many cross-sectional and 
experimental studies have also looked at the amount of human-to-mosquito 
transmission for sub-microscopic infections.66,68–77 However, these modelling, cross-
sectional, and experimental studies focused on submicroscopic infections, which are not 
always asymptomatic. Similarly, asymptomatic infections are not always 
submicroscopic. Thus, the amount of onward transmission caused by asymptomatic 
compared to symptomatic malaria has not been sufficiently assessed and asymptomatic 
malaria’s role as a reservoir has not been clarified. 
Asymptomatic Malaria and Human Health 
The prevalence of asymptomatic malaria varies across groups depending on 
human host factors that influence susceptibility to symptom development. Sex has been 
observed as an effect modifier for asymptomatic and symptomatic infections with males 
experiencing higher prevalence of both infection types.78 Age has also been reported as 
an important factor for malaria infection as young children have the highest risk of 
symptomatic or severe infection.79–81 Additional factors like transmission intensity and 
infection with multiple genetically-distinct malaria parasites (multiclonality) could explain 
susceptibility to symptomatic malaria. Multiclonal infections in older children in high 
transmission areas have been associated with a reduced risk of symptomatic 
malaria,82,83 whereas multiclonal infections in younger children in low transmission 
areas have been associated with an increased risk of symptomatic malaria.84–86  
Because of the high likelihood of being infected with multiple malaria parasites at 
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the same time, it is imperative to assess multiclonality in high malaria transmission 
areas like Kenya.70,87–89 Multiclonality could be an indicator for how haplotype diversity 
influences development of symptomatic infections, with higher haplotype diversity 
protecting against symptomatic progression.90,91 Repeated exposure to haplotypes has 
been hypothesized to create partial anti-disease immunity to those haplotypes, causing 
lower parasite densities and fewer symptomatic infections.92–95 This theory has been 
supported by studies that observed an association between new infections and an 
increased risk of symptomatic illness, finding that an asymptomatic infection rarely 
became symptomatic.20,96–99 Yet, another study observed 47% of children with 
asymptomatic infections later developed symptomatic illness from the initial 
asymptomatic infection.16 We used amplicon deep sequencing technology to assess 
genetically-distinct haplotypes within and between infections during the study period 
and determine if an individual harbors the same parasites in asymptomatic compared to 
symptomatic infections.  
Chronic asymptomatic infections could have negative health consequences.100 
Chronic asymptomatic malaria has been associated with malnutrition;101,102 low platelet 
count and hemoglobin levels in children;103 anemia;101,102,104,105 adverse pregnancy 
outcomes such as preterm birth, low birth weight, and mortality;104,106 invasive bacterial 
infections (non-typhoid salmonellae);107 and cognitive impairment.108 These conditions 
suggest that it could be beneficial to treat asymptomatic infections.  
Conversely, asymptomatic infections could have protective health benefits for the 
individual against future symptomatic infection; however, the relationship between 
asymptomatic malaria and future symptomatic illness is still poorly understood. Some 
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studies observed that having a history of asymptomatic malaria decreased the risk of 
subsequent symptomatic illness.17,19–21 Other reports discovered that an asymptomatic 
infection actually increased the risk of symptomatic malaria.14–16,18 A few studies 
observed the direction of effect to differ even within its study population by age groups 
or transmission intensities.22,23 The contradictory findings could be due to differences in 
study populations, designs, and diagnostic techniques. Yet more information is needed 
to discern how asymptomatic malaria infections are associated with future symptomatic 
disease development.  
Significance 
With our study’s 14 to 29-month longitudinal design and highly-sensitive 
amplicon deep sequencing technology, we were able to build upon previous studies of 
the natural history of asymptomatic malaria. We aimed to fill the gap in knowledge on 
whether asymptomatic infections were associated with future symptomatic illness and if 
new genetically-distinct infections were associated with symptom development. We also 
determined if asymptomatic infections were transmitted to mosquitoes more frequently 
than symptomatic infections and, thus, serving as a reservoir for sustained malaria 
transmission. In order to do this, we investigated the incidence of asymptomatic and 
symptomatic P. falciparum infections in human and mosquito samples collected in 
Webuye, Kenya over 29 months. Study results inform the utility of active test and treat 
strategies for reducing asymptomatic malaria infections in high transmission regions.  
Innovation 
To clarify the impact of asymptomatic malaria on intra-host morbidity and onward 
transmission to mosquitoes, in each of the aims we used enhanced methodology and 
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study design compared to previous work. 
In aim 1A, we used a novel approach to capture how asymptomatic malaria 
varied over 29 months across all ages (range: 1 to 85 years), creating a more complete 
view of infection dynamics compared to previous work. Many prior studies only included 
children,14–16,18,21,23 missing information about infection dynamics across all ages. Past 
studies also failed to measure true asymptomatic exposure length by using infrequent 
cross-sectional surveys to identify asymptomatic infections,15,16,18,19,21–23 coding 
exposure binarily as always being exposed after an asymptomatic infection occurred20 
or only following infections for 9 or 30 days.14,15 We more precisely captured 
asymptomatic malaria exposure using a time-varying method that allowed participants 
to change exposure status throughout follow-up.109  
In aim 1B, we expanded upon previous work by following a diverse parasite 
population for 14 months with frequent sampling and high-resolution parasite 
genotyping (amplicon deep sequencing). This approach overcame limitations in 
previous studies that had small sample sizes with brief follow-up,97–99 infrequent 
sampling,86,99 genotyping approaches with high failure rates,20 and an inability to 
capture multiclonal genotypes.20,86,96–99 Specifically, genotyping approaches that use 
PCR-restricted fragment length polymorphism to detect size variants,20,86,96–99 capture 
only 30% of the unique clones present compared to amplicon deep sequencing.110 Due 
to this inability to capture all clones present,111 prior work employing these approaches 
failed to accurately classify haplotypes as new, recurrent or persistent. Using fine-scale 
genotypes created by the more sensitive amplicon deep sequencing method,110 we 
were able to more definitively partition the distinct effects of new, recurrent or persistent 
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haplotypes within infections, which has previously not been done.16,20,86,96–99 
In aim 2, we built upon previous studies by capturing participant-to-mosquito 
transmission longitudinally, in a larger study population, and in a natural setting with 
mosquitoes collected within participants’ households. Prior studies measured 
participant-to-mosquito malaria transmission using experimental direct or membrane 
feeding by laboratory-reared mosquitoes,59–63 and therefore could not capture variance 
in the feeding behaviors of vectors112 or natural trajectories of infections;113 the feeding 
methods used in these studies failed to represent numerous participant-, mosquito-, and 
parasite-related factors that are critical to transmission, limiting their generalizability. We 
quantified asymptomatic malaria transmission to mosquitoes in a more natural, 
generalizable setting using mosquitoes caught in participants’ households post-
overnight feeding.  
The innovative approaches employed across the three dissertation aims allowed 
us to learn more about the natural history of asymptomatic malaria. Using a novel time-
varying exposure coding method to measure asymptomatic malaria exposure in both 
children and adults, we gained more precise estimates of asymptomatic malaria 
exposure and its influence on subsequent symptomatic illness. Using frequent sampling 
and amplicon deep sequencing methodology, we were able to more finely differentiate 
between new, recurrent, and persistent haplotypes and their association with infection 
dynamics. Finally, we were the first study to estimate participant-to-mosquito malaria 
transmission using amplicon deep sequencing and probabilistic modeling, offering a 






CHAPTER III: METHODS 
 
Study Site 
The longitudinal prospective research study was conducted in Webuye, a town in 
Bungoma East sub-county in Western Kenya. Webuye is in a rural region where most 
residents work in small-scale agricultural practices. In 2009, most of the population had 
access to improved water (88.9%) and sanitation (96.6%), but there was little access to 
electricity (4.5%) and paved roads (6.0%).114 The majority of the sub-county’s 
population lives below the poverty line (52.9%).114 Malaria is a large health issue in the 
sub-county, with malaria listed as the cause of 89.2% of patients’ first outpatient visits to 
a health facility.114 Overall, malaria transmission is high and endemic in Webuye.1 
Transmission has two seasonal peaks following the long rainy season (May to June) 
and the short rainy season (September to October). P. falciparum is the main parasite 
species in the region.1 The major Anopheles mosquito species are An. gambiae, An. 
arabiensis, An. funestus, and An. merus.1  
Study Population 
A longitudinal cohort of individuals residing in 38 households across 3 villages 
(Kinesamo, Maruti, and Sitabicha) was established in June 2017 and followed until 
November 2019. The three villages were selected based on their similar high levels of 
malaria prevalence observed in a previous cross-sectional study in the area [Mean P. 
falciparum prevalence in 2013: Kinesamo (18.4%), Maruti (20.8%), Sitabicha (22.8%)].32 
Within each village, households were enrolled by randomly selecting the index 
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household from among those in the previous cohort and then enrolling additional 
households radially until 12 households were enrolled per village. Two enrolled 
households were replaced with neighboring households when the entire household 
moved out of the study area during follow-up. Participants were excluded from the study 
if they were less than 1-year-old, refused any component of the study or sample 
collection or completed less than 2 months of follow-up. 
Participant Sample Collection and Surveillance 
For each participant, demographic and behavioral questionnaires were 
administered and dried blood spot samples collected every month (Figure 3.1). Dried 
blood spots were collected by pricking the participant’s finger and placing three blood 
spots on filter paper. The questionnaires included malaria-related information 
experienced in the past month, such as travel history, insecticide-treated net (ITN) use, 
malaria-like illness, and antimalarial use. Study participants were invited to contact the 
study team when experiencing malaria-like symptoms; when this occurred, a team 
member visited the participant’s household to record symptoms, collect a dried blood 
spot, and test for P. falciparum malaria using a rapid diagnostic test (RDT) (Carestart © 
Malaria HRP2 Pf from Accessbio).115 If the RDT produced negative results, the 
participant was referred with the test results to the nearest health facility. If the RDT 
produced positive results, the participant received Artemisinin-based Combination 
Therapy (ACT) from the local pharmacy at no charge. Microscopy was not performed. 
Mosquito Collection and Identification 
One morning each week, the study team visited participant households to collect 
indoor resting mosquitoes via vacuum aspiration with Prokopacks.116 Participants were 
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asked to leave windows and doors closed until the study team arrived. Mosquitoes were 
stored in collection cups in boxes with icepacks until they were transported to the 
laboratory in Webuye. Mosquitoes were killed using chloroform and sorted by genus 
(Anopheles or Culex) and sex (male or female). The female Anopheles were speciated 
and dissected between the head and abdomen.  
Participant and Mosquito Sample Processing 
Participant dried blood spot samples and female Anopheles mosquito abdomens 
were shipped to Duke University in Durham, North Carolina, where they were 
molecularly processed to determine P. falciparum infection status and haplotypes. The 
dried blood spots and mosquito parts were distributed into 384-well plates with one 
punched dried blood spot per participant per well and one mosquito abdomen per 
mosquito per well. P. falciparum parasite genomic deoxyribonucleic acid (gDNA) was 
Chelex-extracted from each of the samples. Each sample was tested in duplicate for P. 
falciparum parasites using real-time, quantitative Polymerase Chain Reaction (qPCR) 
and the P. falciparum 364r assay. A human -tubulin assay was also included in the 
qPCR as an internal control. Samples were defined as P. falciparum-positive if: (i) both 
replicates amplified P. falciparum and both Ct values were < 40 or (ii) 1 replicate 
amplified P. falciparum and Ct value was < 38.  
Dual-indexed libraries were prepared for amplicon deep sequencing of the ~300 
nucleotide polymorphic P. falciparum parasite gene targets apical membrane antigen-1 
(pfama1) and circumsporozoite protein (pfcsp) on an Illumina miSeq platform.117 Using 
Trimmomatic, CutAdapt, and BBmap,118–120 sample reads were mapped to the 3D7 
reference sequences for pfama1 and pfcsp and primers removed.121,122 Sample read 
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pairing, haplotype calling, and chimera removal were performed using DADA2 version 
1.8.123 This process outputted haplotypes (distinct sequences of the pfama1 and pfcsp 
gene targets) to be used as a measure of parasite genetic diversity. Haplotypes were 
censored if: (i) supported by < 250 reads within the sample; (ii) supported by < 3% of 
the sample’s total read depth; (iii) deviation from the expected nucleotide length of 300 
for pfama1 or 288 for pfcsp; or (iv) a minority haplotype distinguished by a one single-
nucleotide polymorphism (SNP) difference from another haplotype within the sample 
that had a read depth > 8 times the read depth of the minority haplotype.124 We also 
removed a haplotype from the overall population if it was defined by a single variant 
position that was only variable within that haplotype. All genetic sequences are available 
through the National Center for Biotechnology Information GenBank (BioProject 
Number PRJNA646940).  
Data Analysis 
 The data analysis approach was largely motivated by the high amount of malaria 
transmission in the study site. Malaria endemicity caused a high number of 
asymptomatic and symptomatic infection events, a diverse malaria parasite population, 
and frequent turnover of malaria infections. To capture a more complete picture of 
asymptomatic infection dynamics, we utilized amplicon deep sequencing and multi-level 
modelling methodology. All analyses were conducted using R (versions 3.6.1 or 
4.0.2).125,126 
Aim 1A Analysis 
The main exposure assessed was individual-level exposure to asymptomatic P. 
falciparum infection compared to no P. falciparum infection. Exposure status was 
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ascertained at each monthly follow-up visit and allowed to vary each month using a 
method proposed by Hernán et al.109 The method treated each monthly follow-up visit 
as a new study entry, recalculating the time to symptomatic malaria using the monthly 
follow-up visit date as the origin.109 Participant follow-up was imputed for the first 
consecutive missed monthly visit during each follow-up period using the exposure 
status in the previous month.9 The main outcome assessed was time to symptomatic 
malaria infection (in days). A symptomatic infection was P. falciparum-positive by both 
RDT and qPCR in a participant with at least one symptom consistent with malaria 
during a sick visit. Repeated symptomatic infections were included.  
We compared how the short and long-term hazard of symptomatic illness differed 
across exposure to asymptomatic malaria compared to no malaria infections, expanding 
participant follow-up from 1 to 3, 6, 12, and 29 months. First, we compared time to 
symptomatic malaria stratified by asymptomatic exposure using Kaplan-Meier curves 
and the log-rank test. Next, we assessed the hazard of symptomatic malaria across 
asymptomatic exposure controlling for confounding covariates identified in a directed 
acyclic graph (DAG) analysis and participant-level correlation with a frailty Cox 
proportional hazards model. Effect measure modification by age and sex was assessed 
by stratifying the multivariate frailty Cox proportional hazards model by age category or 
sex. Pre-symptomatic and post-treatment sensitivity analyses were conducted to assess 
differences in model results. 
We also investigated how the detectability of asymptomatic infections affected 
the 1-month, short-term hazard of symptomatic malaria. We compared multivariate 
frailty Cox proportional hazards model results across varying parasite density thresholds 
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as well as malaria diagnostic limits of detection. 
Aim 1B Analysis 
For every person, we classified parasite haplotypes created by amplicon deep 
sequencing in each of their infections as: (i) new, a haplotype not previously observed in 
that person; (ii) recurrent, one previously observed in that person but not in the most 
recent DBS sample; or (iii) persistent, a haplotype previously observed in the most 
recent DBS sample. For the main exposure, we categorized each infection using the 
above haplotype classifications, assigning categories independently for pfama1 and 
pfcsp haplotypes. For the main outcome, each P. falciparum infection was categorized 
as asymptomatic or symptomatic.  
Using a multi-level logistic regression model, we assessed odds of symptomatic 
malaria as a function of new, recurrent or persistent haplotypes in: (i) incident infections 
where none of the haplotypes in the infection were previously observed in the 
participant’s most recent DBS or (ii) persistent infections where at least one haplotype 
persisted between consecutive DBS collections occurring within 30 days. The logistic 
regression model included a participant-level random intercept and controlled for 
confounding covariates identified in a DAG. We evaluated effect measure modification 
by age on the multiplicative scale.  
Aim 2 Analysis 
The main exposure was classification of an infection as asymptomatic or 
symptomatic. To first assess the likelihood of transmission by symptomatic status within 
participants, we compared the proportion of mosquitoes that shared a haplotype 
between a participant’s asymptomatic and symptomatic infections. We computed the 
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proportion of participant-mosquito pairings that shared at least one haplotype across 
participants that had at least one asymptomatic and one symptomatic infection. We 
assessed the statistical significance of differences in these proportions between 
asymptomatic and symptomatic infections using a multi-level logistic regression model 
that included random intercepts at the participant and household levels and controlled 
for confounding covariates.  
For a more comprehensive measure of transmission across all participants, we 
created a probabilistic model to estimate the probability that a shared haplotype 
between a participant and a mosquito represented a P. falciparum transmission event. 
The probability of transmission estimate was based on three distinct features: (i) the 
time interval between the participant’s infection and mosquito collection; (ii) the distance 
between the household of the participant and the household where the mosquito was 
collected; and (iii) the prevalence and number of parasite haplotypes shared. We 
compared values between participants with asymptomatic and symptomatic infections 
using a multi-level logistic regression model with random intercepts at the participant 
and household levels as well as confounding covariates as identified in a DAG analysis. 
Sensitivity analyses were conducted to compare coding choices for the probabilistic 
combination of time, distance, and haplotypes.  
The contribution to the infectious reservoir made by asymptomatic infections was 
calculated using the odds ratio estimate obtained from the probabilistic method for 




Figure 3.1. Follow-up visit and sample collection design.  
The first 14 months of participant follow-up and mosquito collections are illustrated 
below. This follow-up design was repeated for up to 29 months for aim 1A and 14 













CHAPTER IV: IMPACT OF ASYMPTOMATIC PLASMODIUM FALCIPARUM 
INFECTION ON THE RISK OF SUBSEQUENT SYMPTOMATIC MALARIA IN A 
LONGITUDINAL COHORT IN KENYA 
 
Introduction 
Asymptomatic Plasmodium falciparum infections are common across sub-
Saharan Africa, with a meta-analysis estimating that 24% of the continent’s children 
harbored an asymptomatic infection in 2015.35 When such infections persist chronically 
they can have adverse effects on the host101,102,104,105 as well as serve as a reservoir for 
malaria transmission.61,62  
Because of the potential for adverse effects from asymptomatic infections, it is 
important to learn more about the natural history of asymptomatic P. falciparum and its 
implications for future symptom development. Previous studies observed that a history 
of asymptomatic malaria decreased the risk of subsequent symptomatic infection,17,19–21 
while others reported that exposure to asymptomatic malaria actually increased the risk 
of symptomatic illness.14–16,18 A few studies observed the direction of effect even 
differed within its study population based on age or transmission intensity.22,23 Many of 
these studies had infrequent cross-sectional surveys for asymptomatic 
infections,16,18,19,21–23 short follow-up periods,14,15 or assessment of only children,14–
16,18,21,23 possibly missing informative asymptomatic events across a range of ages and, 
thus, not fully capturing the natural history of asymptomatic malaria.   
 We investigated the natural history of asymptomatic P. falciparum infections in a 
high-transmission setting using a 29-month longitudinal cohort of people aged 1 to 85 
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years in Western Kenya. Using monthly active case detection of asymptomatic 
infections and passive capture of symptomatic events, we investigated the likelihood of 
symptomatic malaria following an asymptomatic P. falciparum infection. Because 
asymptomatic malaria could be indicative of a pre-symptomatic state, we hypothesized 
that, compared to uninfected people, those with an asymptomatic infection would have 
a higher short-term hazard of symptomatic malaria.  
Materials and Methods 
Study Population, Sample Collection, and Sample Processing 
From June 2017 to November 2019 we followed a cohort of 268 people aged 1 to 
85 years living in 38 households in a rural setting in Webuye, Western Kenya.127 For 
each person, asymptomatic P. falciparum infections were detected monthly by active 
surveillance through collecting questionnaires and dried blood spot (DBS) samples for 
post-hoc molecular parasite detection. Symptomatic P. falciparum infections were 
detected using passive surveillance by testing people with self-reported symptoms with 
a malaria rapid diagnostic test (RDT) (Carestart© Malaria HRP2 Pf from Accessbio) and 
collecting a DBS.115 People with positive RDT results were treated with Artemether-
Lumefantrine (AL).  
DBS were processed to detect P. falciparum infections by extracting genomic 
DNA (gDNA) from DBS and then tested in duplicate for P. falciparum parasites using a 
duplex real-time PCR (qPCR) assay targeting the P. falciparum pfr364 motif and human 
-tubulin gene.128,129 Samples were defined as P. falciparum-positive if: (i) both 
replicates amplified P. falciparum and both Ct values were < 40 or (ii) 1 replicate 
amplified P. falciparum and the Ct value was < 38. Parasite density was estimated 
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against a standard curve included on each qPCR reaction plate consisting of templates 
at known parasite densities ranging from 1 to 2,000 parasites/L. 
Exposure and Outcome Ascertainment 
The main exposure was an asymptomatic P. falciparum infection during monthly 
active case detection assessments, defined as P. falciparum-positive by qPCR in a 
person lacking symptoms. People who were P. falciparum-negative by qPCR during 
monthly visits were considered uninfected. Participant follow-up was imputed for the first 
consecutive missed monthly visit during each follow-up period. The exposure status in 
the previous month was assumed to be the exposure status of the missed monthly 
visit.9 If a person missed two or more consecutive monthly visits, they were considered 
lost to follow-up and censored at the time of the imputed monthly visit. 
The main outcome assessed was days to symptomatic malaria infection. We 
defined symptomatic P. falciparum infection as the presence of at least one symptom 
consistent with malaria during a sick visit and P. falciparum-positive by both RDT and 
qPCR. Sensitivity analyses for which alternate definitions of symptomatic malaria were 
used are reported in the supplement. Events occurring within 14 days of receipt of AL 
for a symptomatic infection were censored. Participants were allowed to enter and leave 
the study throughout the study period. At the end of the study period, all participants 
were censored.  
Hazard of Symptomatic Malaria Analysis 
Across all participants, we estimated the hazard of subsequent symptomatic 
malaria when infected with asymptomatic malaria compared to being uninfected at 
monthly visits. The hazard of symptomatic malaria was calculated within multiple follow-
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up periods: (i) 1 month; (ii) 3 months (iii) 6 months; (iv) 12 months; and (v) 29 months 
(entire study period). For each follow-up period exceeding 1 month, exposure status 
was ascertained at every monthly visit and allowed to vary each month using a method 
proposed by Hernán et al.109 The method treated each monthly follow-up visit as a new 
study entry, recalculating the time to symptomatic malaria or censoring using each 
monthly follow-up visit date as the origin and attributing the exposure in that month as 
the exposure status from that month up until the event or censoring occurred (Figure 
4.1). Results predicted the likelihood of symptomatic illness within 1 month, 3 months, 6 
months, etc. when harboring an asymptomatic infection versus being uninfected during 
each follow-up period. This exposure coding method was chosen due to its ability to 
capture the exposure at multiple time points with less risk of misclassification or left 
truncation bias compared to alternative time-varying coding approaches (Table S4.1). 
Statistical Modeling 
We first estimated the time to symptomatic malaria using Kaplan-Meier curves 
and the log-rank test. Differences in median time to symptomatic malaria were also 
compared across select covariates using the Wilcoxon Rank Sum test with continuity 
correction for dichotomous variables or the Kruskal-Wallis test for polytomous variables. 
The Bonferroni correction was applied to all table p-values to account for repeated 
measures during the 29 months of follow-up. 
In order to account for anticipated confounders of the relationship between 
asymptomatic infection and symptomatic malaria, we next computed a multivariate 






=  exp(𝛼𝑖 + 𝛽1𝐴𝑦𝑚𝑝𝑡𝑜𝑚𝑎𝑡𝑖𝑐 𝑖𝑛𝑓𝑒𝑐𝑡𝑖𝑜𝑛𝑖𝑚 + 𝛽2𝐴𝑔𝑒5𝑡𝑜15𝑖 + 𝛽3𝐴𝑔𝑒𝑜𝑣𝑒𝑟15𝑖 +
 𝛽4𝐹𝑒𝑚𝑎𝑙𝑒𝑖 + 𝛽5𝑅𝑒𝑔𝑢𝑙𝑎𝑟 𝑏𝑒𝑑 𝑛𝑒𝑡 𝑢𝑠𝑎𝑔𝑒𝑖 + 𝛽6𝑉𝑖𝑙𝑙𝑎𝑔𝑒: 𝑀𝑎𝑟𝑢𝑡𝑖 + 𝛽7𝑉𝑖𝑙𝑙𝑎𝑔𝑒: 𝑆𝑖𝑡𝑎𝑏𝑖𝑐ℎ𝑎 +
𝜖𝑖)                                                                                                                                                      (4.1) 
The model controlled for the following confounders as determined by a directed acyclic 
graph (Figure S4.1): age (<5 years, 5-15 years, >15 years), sex, and regular bed net 
usage (averages > 5 nights a week sleeping under a bed net – yes, no). To account for 
differences in malaria prevalence across the three villages, we also included a covariate 
in the model to represent each village. We allowed the main exposure to vary each 
month based on the monthly follow-up visit infection status (𝑚). A random effect at the 
participant level (𝛼𝑖) accounted for potential correlated outcomes due to multiple 
observations per person. The proportional hazards assumption was assessed using 
Kaplan-Meier curves and Schoenfeld residual plots.  
We tested for effect measure modification by age and sex by stratifying the 
multivariate frailty Cox proportional hazards model by age category (<5 years, 5-15 
years, >15 years) or sex. Hazard ratios and 95% confidence intervals of the main effect 
of interest were compared across stratified models. The log-likelihood ratio test 
compared a Cox proportional hazards model with an interaction term between the 
potential modifier and main exposure to Equation 4.1.  
We computed two additional time-to-event models of the relationship between 
asymptomatic infection and subsequent symptomatic illness using alternate subsets of 
events. Firstly, because asymptomatic infections could represent incipiently 
symptomatic (i.e. “pre-symptomatic”) infections, we conducted an analysis in which all 
monthly follow-up visits occurring within 14 days prior to a symptomatic infection were 
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excluded, reducing the possibility that pre-symptomatic infections could be misclassified 
as asymptomatic. The analysis was conducted using Equation 4.1 for the 1, 3, 6, 12, 
and 29-month follow-up periods. Secondly, to investigate this relationship following the 
definitive clearance of parasites, we conducted an analysis in which participants did not 
enter the analysis until 14 days following AL treatment for a symptomatic episode. This 
analysis focused only on the 1-month hazard of symptomatic malaria and used the 
frailty Cox proportional hazards model described in Equation 4.1. Differences in the 
post-treatment and main analysis data sets were compared using the Pearson’s 2 test 
with Bonferroni correction for 29 months of follow-up. All statistical analyses were 
performed using R (version 4.0.2)125 with the packages tidyverse,130 survminer,131 
survival,132 coxme,133 lme4,134 and ggalluvial.135 Statistical significance was assessed at 
an  level of 0.05. 
Detectability of Asymptomatic Infections 
To investigate how detectability of asymptomatic infections influenced results, we 
assessed how the parasite density of asymptomatic infections changed the 1-month 
hazard of symptomatic malaria. To do so, asymptomatic infections defined as above 
were further classified as meeting a series of thresholds of parasite densities: any 
density, >1, > 10, > 100, > 500, and > 1000 parasites/L. These classifications were 
assigned in a non-mutually exclusive fashion to asymptomatic infections, and then the 
1-month likelihood of symptomatic malaria relative to uninfected people was modeled 
using the Cox proportional hazards model in Equation 4.1. Because parasite density 
influences infections’ detectability by common diagnostics, we next projected the 
likelihood of detection by available diagnostics onto these asymptomatic infections and 
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estimated the risk of progression to symptomatic malaria as a function of likely 
detectability. To do so, we compared the hazard of symptomatic malaria among people 
who were uninfected to those with asymptomatic infections that would have been 
detectable by: (i) qPCR (>0 parasites/L), (ii) highly-sensitive (HS)-RDT ( 1 
parasites/L), (iii) conventional RDT ( 100 parasites/L), or (iv) light microscopy ( 500 
parasites/L). Each asymptomatic infection was classified as detected or undetected by 
each diagnostic’s threshold, and then we used the Cox proportional hazards model in 
Equation 4.1.  
Ethical Considerations 
The study was approved by institutional review boards of Moi University 
(2017/36), Duke University (Pro00082000), and the University of North Carolina at 
Chapel Hill (19-1273). All participants provided written informed consent, and those over 
age 8 provided additional assent.  
Results 
For 29 months, we followed 268 participants from three villages in Western 
Kenya. After excluding participants with less than two months of follow-up, the analysis 
data set consisted of 257 participants with a median of 222 days (interquartile range 
(IQR): 89 to 427) of follow-up. Overall, 5379 person-months at risk were observed with 
1842 (34.2%) person-months of asymptomatic malaria exposure. Exposure status 
frequently changed for participants and remained constant for only 16 (6.2%) people 
across follow-up (Figure 4.2A). We recorded 266 symptomatic malaria events. 
Participants had a median of 1 (IQR: 0, 2) symptomatic infection during follow-up. 
Median time to symptomatic malaria when asymptomatically-infected (173, IQR: 49, 
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399) was shorter than when uninfected (230, IQR: 98, 402), as well as shorter for 
participants aged 5-15 years or living in the village Maruti (Table 4.1). However, 
comparison of Kaplan-Meier curves did not indicate a significant difference in the 
median time to symptomatic malaria by asymptomatic infection for the full 29 months (p-
value = 0.100 by log-rank test) (Figure 4.2B). Results for secondary case definitions for 
symptomatic malaria were overall similar and are provided in the supplement (Tables 
S4.2 and S4.3). 
Short-term Effect of Asymptomatic Malaria Exposure 
In a univariate frailty Cox proportional hazards model, compared to uninfected 
people, the 1-month crude Hazard Ratio (HR) of symptomatic malaria for participants 
with asymptomatic infections was 2.69 [95% confidence interval (CI): 2.12 to 3.43]. This 
association was similar in a model controlling for covariates [adjusted HR: 2.61, 95% CI: 
2.05 to 3.33] (Table 4.2, Figure 4.3A) as well as when using alternative modeling 
approaches and case definitions for symptomatic malaria (See supplemental 
information). This relationship between asymptomatic malaria and subsequent 
symptomatic illness was not modified by age (p-value = 0.447 by log-likelihood ratio 
test). Asymptomatic infections were associated with increased likelihoods of subsequent 
symptomatic malaria in all age categories: < 5 years [HR: 3.77, 95% CI: 2.02 to 7.04], 5-
15 years [HR: 2.45, 95% CI: 1.79 to 3.35], and > 15 years [HR: 2.55, 95% CI: 1.57 to 
4.15] (Table S4.4). In contrast, sex did modify this relationship (p-value = 0.006 by log-
likelihood ratio test) (Table S4.4), whereby the risk of symptomatic malaria following 
asymptomatic infection was lower for males [HR: 1.76, 95% CI: 1.24 to 2.50] compared 
to females [HR: 3.71, 95% CI: 2.62 to 5.24] (Figure S4.2).  
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In subset analyses, compared to uninfected people, the hazard of symptomatic 
malaria was increased in those with asymptomatic infections by more than 1.7 times 
[HR: 1.77, 95% CI: 1.26 to 2.47] when limited to those with events more than 14 days 
after exposure ascertainment (Figure 4.3A) and more than 2.5 times [HR: 2.54, 95% 
CI: 1.76 to 3.67] when limited to those following antimalarial treatment (Figure 4.3A). 
Effect measure modification by neither participant age nor sex was observed in these 
subset analyses (Table S4.4). The post-treatment analysis, which sampled a population 
with at least one symptomatic infection, had significantly more participants that identified 
as female and were 5-15 years-old compared to the full, main analysis data set (Table 
S4.5).  
Long-term Effect of Asymptomatic Malaria Exposure 
Next, we assessed the relationship between asymptomatic infection and 
subsequent symptomatic malaria using prolonged follow-up. Extending the follow-up 
period led to a diminution in the hazard ratios of symptomatic malaria comparing those 
asymptomatically-infected versus uninfected over the following 3 [HR: 1.64, 95% CI: 
1.40 to 1.94], 6 [HR: 1.38, 95% CI: 1.20 to 1.58], 12 [HR: 1.12, 95% CI: 1.00 to 1.25], 
and 29-month [HR: 1.11, 95% CI: 1.01 to 1.22] time periods (Table 4.2, Figure 4.3B). In 
the 29-month analysis, this relationship was modified by participant age (p-value < 
0.001 by log-likelihood ratio test) with the strongest relationship between asymptomatic 
infection and future symptomatic malaria in children < 5 years [HR: 1.38, 95% CI: 1.05 
to 1.81], second-strongest in children 5-15 years [HR: 1.16, 95% CI: 1.02 to 1.32], and 
weakest in adults > 15 years [HR: 0.96, 95% CI: 0.81 to 1.13] (Table S4.4). Consistent 
with the 1-month analysis, we observed modification by sex in some models, with 
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females having higher risk for symptomatic disease (Table S4.4). Results from 
sensitivity analyses are recorded in the supplement (Table S4.4).  
Short-term Effect of Detectability of Asymptomatic Infections 
Owing to the consistently elevated short-term risk of symptomatic malaria in 
people with asymptomatic infections, we investigated the effect of parasite density in 
these infections on the likelihood of subsequent symptomatic malaria with 1 month. 
Compared to uninfected people, the risk of symptomatic malaria was significantly 
increased by asymptomatic infections of all parasite densities, with the highest adjusted 
hazard for those with densities > 1000 parasites/L [HR 3.99, 95% CI 2.41 to 6.62] 
(Figure 4.4A). To the density of each asymptomatic infection, we applied a threshold of 
detectability for parasite diagnostics and estimated the 1-month hazard of subsequent 
symptomatic malaria as a function of detectability by qPCR, HS-RDT, RDT, and light 
microscopy. In this analysis, relative to uninfected people, the hazard of symptomatic 
malaria was increased among people with asymptomatic infections detectable by qPCR 
[HR: 1.70, 95% CI: 1.33 to 2.17], HS-RDT [HR: 2.11, 95% CI: 1.63 to 2.72], RDT [HR: 
1.93, 95% CI: 1.36 to 2.74], and light microscopy [HR: 2.41, 95% CI: 1.56 to 3.71] 
(Figure 4.4B).  
Discussion 
Using a 29-month longitudinal cohort based in a high malaria transmission region 
of Kenya, we investigated the influence of asymptomatic P. falciparum infections on the 
risk of symptomatic malaria. In the short term, compared to uninfected individuals, 
people with asymptomatic infections had a more than 2-fold increased risk of 
symptomatic malaria within 1 month irrespective of patient age. Additionally, this 
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elevated risk of symptomatic malaria was associated with asymptomatic infections at 
densities detectable by all parasite detection approaches. As follow-up time was 
expanded, the association between asymptomatic infection status and the hazard of 
subsequent symptomatic malaria remained overall positive but weakened. Collectively, 
our finding that detection of an asymptomatic P. falciparum infection confers an 
elevated risk of future symptomatic malaria supports the routine treatment of infections 
even in the absence of symptoms.  
We observed that asymptomatic infections were associated with a 2.6-times 
increased risk of symptomatic malaria within 1 month. This association was consistent 
when using multiple case definitions for symptomatic malaria and in pre-symptomatic 
and post-treatment sensitivity analyses. Previous studies that detected asymptomatic 
infections using microscopy also reported an increased short-term hazard of 
symptomatic illness among children within 9 to 30 days after having an asymptomatic 
malaria infection.14,15 We built upon these studies by detecting asymptomatic infections 
using qPCR, a highly sensitive method with a low limit of detection,129 in participants of 
all ages and similarly found that asymptomatic infections had a high probability of being 
quickly followed by symptomatic illness. The increased short-term hazard could be due 
to acquisition of new blood-stage parasites20 or progression of the original infection to 
symptoms;14 however, because this positive association was upheld in sensitivity 
analyses that accounted for misclassification of asymptomatic infections as pre-
symptomatic, the increased hazard observed was not driven solely by pre-symptomatic 
infections. We observed an increased short-term hazard of symptomatic malaria after 
asymptomatic infection regardless of participant age, which suggests that even adults 
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with low density asymptomatic infections have an increased 1-month, short-term hazard 
of symptomatic malaria.  
This elevated risk of symptomatic malaria was present for asymptomatic 
infections at any parasite density and detectability by field diagnostics. Notably, this 
increased hazard of symptomatic malaria grew when harboring asymptomatic infections 
with higher parasite densities. Our results were similar to previous work that also 
observed higher parasite densities increased the odds of subsequent symptomatic 
illness.14,85 This association has been used to prioritize high density, easily detectable 
infections for treatment; however, this prioritization is not representative of long-term 
infection dynamics, as low parasite density infections have been observed to later 
develop into higher density ones.9,136 Additionally, we found that asymptomatic 
infections at all parasite densities, even those detectable by qPCR, were at higher risk 
of symptomatic illness. Thus, our results do not support the notion that parasite 
detectability should be used to risk stratify people for treatment. 
We found that, compared to males, asymptomatically-infected females had a 
statistically significant higher hazard of symptomatic malaria shortly following an 
asymptomatic infection. This was in contrast to previous work in high malaria 
transmission regions that observed higher general malaria burden among 
males;78,137,138 however, no previous longitudinal studies of time-to-symptomatic malaria 
have compared the hazard of symptomatic illness stratified by asymptomatically-
infected males and females, with most studies only including sex as a covariate in 
models. This stratification of asymptomatic infections by sex could have important 
biological implications for the natural history of asymptomatic infections, as recent 
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research has suggested that females clear asymptomatic infections faster than 
males.139 More research is needed to determine potential mechanisms for sex-based 
differences in the hazard of symptomatic malaria following an asymptomatic infection.   
We observed that the elevated risk for symptomatic disease associated with 
asymptomatic infection weakened as the follow-up length expanded from 3 to 29 
months. In fact, the hazard of symptomatic illness was only significantly increased for up 
to 6 months following an asymptomatic infection. This phenomenon has been previously 
observed as a methodological flaw for hazard ratios, whereby the magnitude of the 
average hazard ratio decreases as follow-up time increases,140 and possibly explains 
previous conflicting studies with variable long-term follow-up: some previous work found 
an increased risk of future symptomatic illness within 9-12 months when infected with 
asymptomatic malaria16,18 but those with greater than 1 year of follow-up observed a 
decreased risk.19–21,141 Thus, the follow-up period is a critical factor for assessing the 
relationship between asymptomatic infection and the future hazard of symptomatic 
malaria. We addressed this potential issue by presenting a series of average hazard 
ratios over a range of follow-up periods and encourage future studies to employ this 
approach.  
We used a novel approach to capture how asymptomatic malaria varied over 
time. Most previous work used an intention-to-treat approach for asymptomatic 
infections identified in cross-sectional surveys;16–19,21–23 however, this method can 
misclassify person-time if the exposure frequently changes, as happens with 
asymptomatic infections in high transmission areas. For previous studies with more 
frequent asymptomatic sampling, the projects had short follow-up periods (9-30 
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days)14,15 that obscured the true duration of asymptomatic infection, or coded the 
exposure as always being exposed after an asymptomatic infection occurred.20 We 
more precisely recorded asymptomatic malaria exposure using a time-varying method 
proposed by Hernán et al.109 that allowed participants to change exposure status 
throughout follow-up, capturing a more complete view of infection dynamics with lower 
risk of exposure misclassification. This new method produced an effect estimate 
predictive of future risk regardless of prior exposure making it also less prone to left 
truncation bias, which can occur with methods that create additive measures of months 
of exposure. The Hernán et al.109 method has been used in previous studies of 
cardiovascular or kidney disease,142–144 but has never before been used to study 
malaria. We urge more studies to incorporate frequent longitudinal sampling of 
asymptomatic infections into time-to-symptomatic malaria analyses as well as to include 
new time-varying exposure methodology.  
This study had some limitations. Asymptomatic infections were only captured at 
monthly follow-up visits, missing transient asymptomatic infections between visits. By 
allowing participant exposure to vary over time, we assumed exchangeability between 
the exposed and unexposed groups. This was mitigated by the observation that 
approximately 94% of the study population changed exposure status at least once 
during follow-up. Finally, we detected asymptomatic infections only by qPCR and 
estimated parasite densities only using molecular methods. However, we estimated the 
influence of detectability of asymptomatic malaria using commonly-accepted thresholds 
for clinical diagnostics. 
In conclusion, using a novel exposure coding method and frequent sampling of 
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both children and adults over 29 months, we found that asymptomatic P. falciparum 
infections had a high likelihood of being shortly followed by symptomatic illness across 
all ages and parasite densities. These results suggest interventions focus on treating 








Abbreviations: IQR, interquartile range 
#Regular bed net usage was a person averaging > 5 nights a week sleeping under a bed net. 
*Total person-months indicates the total number of monthly follow-up visits ending in a 
symptomatic infection or censoring for full 29-month follow-up. 
**Symptomatic infections were defined using the primary case definition where a participant was 
P. falciparum-positive by both RDT and qPCR as well as had at least one symptom consistent 
with malaria during a sick visit. 
a Wilcoxon Rank Sum test with continuity correction and Bonferroni correction for repeated 
measures. 
b Kruskal-Wallis test with Bonferroni correction for repeated measures. 





















Main exposure    <0.001a 
    No infection 3537 (65.8) 1580 (65.7) 230 (98, 402) - 
    Asymptomatic infection 1842 (34.2) 826 (34.3) 173 (49, 399) - 
Age    0.015b 
    < 5 years 812 (15.1) 329 (13.7) 226 (82, 435) - 
    5-15 years 2279 (42.4) 1319 (54.8) 199 (70, 379) - 
    > 15 years 2288 (42.5) 758 (31.5) 244 (97, 426) - 
Sex    0.779a 
    Male 2360 (43.9) 1190 (49.5) 229 (86, 420) - 
    Female 3019 (56.1) 1216 (50.5) 202 (76, 384) - 
Regular bed net usage#    1.000a 
    No 1425 (26.5) 730 (30.3) 210 (82, 386) - 
    Yes 3954 (73.5) 1676 (69.7) 217 (80, 403) - 
Village    <0.001b 
    Kinesamo 1854 (34.5) 876 (36.4) 233 (89, 418) - 
    Maruti 1681 (31.3) 745 (31.0) 174 (64, 350) - 
    Sitabicha 1844 (34.3) 785 (32.6) 231 (90, 421) - 
     
 
 
Table 4.2. Predicted hazard of symptomatic malaria across follow-up periods 
 
 
Abbreviations: CI, confidence interval; HR, adjusted hazard ratio; IQR, interquartile range; Ref, reference 
#Regular bed net usage was defined as a person averaging > 5 nights a week sleeping under a bed net. 
*Total person-months indicates the total number of monthly follow-up visits ending in a symptomatic infection or censoring. 
**Symptomatic infections were defined using the primary case definition where a participant was P. falciparum-positive by both RDT 
and qPCR as well as had at least one symptom consistent with malaria during a sick visit. 
a Wilcoxon Rank Sum test with continuity correction and Bonferroni correction for repeated measures. 
b Kruskal-Wallis test with Bonferroni correction for repeated measures. 
Significant estimates are bolded.  
 
1-month 
HR (95% CI) 
3-month 
HR (95% CI) 
6-month 
HR (95% CI) 
12-month 
HR (95% CI) 
29-month 
HR (95% CI) 
Main exposure      
    No infection Ref Ref Ref Ref Ref 
    Asymptomatic infection 2.61 (2.05, 3.33) 1.64 (1.40, 1.94) 1.38 (1.20, 1.58) 1.12 (1.00, 1.25) 1.11 (1.01, 1.22) 
Age      
    < 5 years Ref Ref Ref Ref Ref 
    5-15 years 1.37 (0.90, 2.08) 1.61 (1.00, 2.61) 1.99 (1.07, 3.71) 2.37 (0.97, 5.77) 2.52 (1.26, 5.01) 
    > 15 years 0.56 (0.36, 0.88) 0.74 (0.46, 1.21) 0.83 (0.44, 1.53) 0.88 (0.37, 2.08) 0.97 (0.51, 1.84) 
Sex      
    Male Ref Ref Ref Ref Ref 
    Female 0.93 (0.70, 1.24) 0.84 (0.61, 1.16) 0.80 (0.53, 1.20) 0.68 (0.38, 1.21) 0.63 (0.40, 0.99) 
Regular bed net usage#      
    No Ref Ref Ref Ref Ref 
    Yes 1.00 (0.70, 1.43) 0.81 (0.55, 1.20) 0.70 (0.43, 1.16) 0.59 (0.29, 1.21) 0.52 (0.30, 0.89) 
Village      
    Kinesamo Ref Ref Ref Ref Ref 
    Maruti 1.08 (0.77, 1.52) 1.11 (0.75, 1.64) 1.14 (0.69, 1.88) 1.13 (0.56, 2.31) 1.09 (0.64, 1.85) 
    Sitabicha 0.72 (0.49, 1.05) 0.80 (0.53, 1.21) 0.76 (0.45, 1.29) 0.73 (0.35, 1.51) 0.70 (0.40, 1.23) 







Figure 4.1. Schematic of how asymptomatic exposure status was ascertained for 
one participant’s follow-up using the Hernán et al. method. 
The method treated each monthly follow-up visit as a new study entry for the participant, 
recalculating the time to symptomatic malaria using the monthly follow-up visit date as 
the origin. The exposure status for each monthly follow-up visit became the exposure 
status for the follow-up period. The follow-up period ended if the participant had a 
symptomatic infection or was censored due to the study ending or becoming lost to 








Figure 4.2. Asymptomatic malaria versus no infection exposure classification 
over time. 
4.2A: The proportion of participants who had either an asymptomatic infection (orange) 
or no infection (green) at each monthly visit is indicated by the bars. The ribbons 
connecting the bars illustrate the proportion of participants who moved exposure status 
from month to month. Orange ribbons indicate the proportion of participants with 
asymptomatic infections and green the proportion with no infection. 4.2B: A Kaplan-
Meier survival curve assessing median time to symptomatic malaria is illustrated across 






Figure 4.3. Hazard of symptomatic malaria after exposure to asymptomatic 
infections compared to no malaria infection over time. 
4.3A: Frailty Cox proportional hazards model results comparing exposure to 
asymptomatic malaria infections versus no infection over time and hazard of 
symptomatic malaria in the main model using the primary outcome coding as well as 
across exposure and outcome sensitivity analyses. The pre-symptomatic analysis 
model removed monthly follow-up visits that occurred within 14 days prior to a 
symptomatic malaria infection. The post-treatment analysis model was restricted to only 
participants who had at least one symptomatic malaria infection and follow-up began at 
the monthly visit at least 14 days post study-administered antimalarial treatment for 
each person’s initial symptomatic infection. All models controlled for covariates 
participant age, sex, bed net usage, and village. 4.3B: Models were run with differing 
follow-up for each participant ranging from 1 to 29 months and controlled for covariates 





Figure 4.4. Detectability of asymptomatic malaria infections and short-term 
hazard of symptomatic malaria. 
4.4A: Frailty Cox proportional hazards model results for the short-term, 1-month hazard 
of symptomatic malaria comparing models restricted to asymptomatic infections with 
varying parasite density thresholds in parasites/L (p/L) across malaria diagnostics. All 
models compared asymptomatic malaria exposure to no infection exposure and 
controlled for covariates participant age, sex, bed net usage, and village. 4.4B: Frailty 
Cox proportional hazards model results for the 1-month hazard of symptomatic malaria 
comparing models with asymptomatic infections with varying detectability across 
malaria diagnostics. Models compared asymptomatic malaria exposure to having no 
infection over time and controlled for covariates participant age, sex, bed net usage, 









CHAPTER V: EXPOSURE TO DIVERSE PLASMODIUM FALCIPARUM GENOTYPES 
SHAPES THE RISK OF SYMPTOMATIC MALARIA IN INCIDENT AND PERSISTENT 




Plasmodium falciparum causes over 200 million clinical malaria cases 
annually.145 Many of these infections occur in young children, who are more likely to 
develop symptomatic malaria compared to adults.19,78,146 This age-dependent risk of 
symptomatic disease is thought to develop following repeated exposure to P. falciparum 
that produces adaptive, disease-controlling immune responses.92–95,147 The targets and 
mechanisms of this naturally-acquired immunity remains largely obscure. 
In the absence of generalizable, measurable immune correlates, the contours of 
functional clinical immunity to parasites and disease have been inferred from patterns of 
disease risk and parasite genetics. Specifically, the adaptive immunity theory has been 
supported by studies reporting that symptomatic malaria is often associated with the 
presence of parasite genotypes that were unobserved in prior infections;20,86,96–99 this 
suggests that symptomatic malaria results from new infections that can exploit gaps in 
immunologic memory. These prior studies, though, have been limited in scope and 
follow-up,86,97–99 resolution of genotyping approach,20,86,96–99 and an inability to partition 
effects of parasite genotypes between newly-acquired and persistent infections, which 
collectively limit the generalizability of findings. Furthermore, most20,86,97–99 have 
interrogated neutral parasite genes that do not clearly encode targets of functional 
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immunity, which further limits causal inference of immunologic mechanisms. A clearer 
understanding of the influence of parasite genetic diversity on disease risk would inform 
the development of polyvalent vaccines. 
To explore how the specific P. falciparum infections acquired over time influence 
the risk of symptomatic malaria, we investigated the association between Plasmodium 
falciparum genotypes and an individual’s risk of symptomatic infection using a 14-month 
longitudinal cohort in Western Kenya. To do so, we classified each person’s infections 
as harboring novel, recurrent or persistent parasites on the basis of amplicon deep 
sequencing of two diverse parasite genes that encode targets of known functional 
immunity at the liver (circumsporozoite protein, pfcsp) and blood (apical membrane 
antigen-1, pfama1) stages, and analyzed associations between haplotype categories 
and the odds of developing symptomatic malaria. We hypothesized that, compared with 
infections harboring parasite genotypes previously observed within a person’s prior 
infections, infections harboring hitherto-unobserved haplotypes would be associated 
with increased likelihood of symptomatic malaria. 
Materials and Methods 
Study Population and Sample Collection 
From June 2017 to July 2018, a longitudinal cohort was followed in Webuye, 
Western Kenya, consisting of members 1 to 85 years of 38 randomly-selected 
households.127 Asymptomatic P. falciparum infections were detected by active case 
detection using monthly dried blood spot (DBS) collection, in which parasites were 
detected by real-time PCR (qPCR; see below). Symptomatic malaria infections were 
detected by passive surveillance whereby participants experiencing malaria-like 
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symptoms contacted the study team, were tested for malaria using a rapid diagnostic 
test (RDT; Carestart© Malaria HRP2 Pf from Accessbio),115 and had a DBS collected. 
RDT-positive participants were treated with Artemether-Lumefantrine.  
Sample Processing 
Molecular sample processing has been previously described. Genomic DNA 
(gDNA) was extracted from DBS using Chelex-100 and tested in duplicate for P. 
falciparum parasites using a duplex qPCR assay targeting the P. falciparum pfr364 
motif and human -tubulin gene.128,129 P. falciparum-positive samples were genotyped 
across gene segments encoding pfama1 and pfcsp using PCR amplification and 
sequencing on an Illumina MiSeq platform.117,148 Read processing and haplotype 
inference were as previously described;149 briefly, reads were quality-filtered and 
mapped to the 3D7 reference sequences for pfama1 and pfcsp.121,122,148 Haplotype 
inference was performed on mapped reads using DADA2 (version 1.8) as implemented 
in R (version 4.0.2)123,125 and resulting haplotypes were further filtered to reduce 
haplotype false discovery risk using previously-validated criteria.124 The output was a 
catalog of all pfcsp and pfama1 unique haplotypes in each qPCR-positive infection for 
each person. Sequences are available through GenBank (PRJNA646940).  
Exposure and Outcome Assessment 
For every person, we classified each parasite haplotype in each of their 
infections as: (i) new, a haplotype not previously observed in that person; (ii) recurrent, 
one previously observed in that person but not in the most recent DBS sample; or (iii) 
persistent, a haplotype previously observed in the most recent DBS sample irrespective 
of whether the sample was a routine monthly sample or a symptomatic event (Figure 
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5.1). For the main exposure, we categorized each infection using the above haplotype 
classifications, and therefore each infection could contain a mixture of new, recurrent or 
persistent haplotypes; these categories were assigned independently for pfama1 and 
pfcsp haplotypes. 
For the main outcome, each P. falciparum infection was categorized as 
asymptomatic or symptomatic. An asymptomatic infection was P. falciparum-positive by 
qPCR in a person lacking symptoms and seen during monthly follow-up visits. A 
symptomatic infection was P. falciparum-positive by both RDT and qPCR in a 
participant with at least one symptom consistent with malaria during a sick visit. 
Infections were excluded from the outcome ascertainment process if they occurred 
within 14 days of taking Artemether-Lumefantrine for a symptomatic infection or were 
the person’s first infection during the study (which would harbor only new haplotypes). 
To assess potential for pre-symptomatic infections, across all symptomatic infections, 
we compared the time since the preceding asymptomatic infection between infections 
with and without persistent haplotypes using a Kruskal-Wallis 2 test.   
We assessed odds of symptomatic malaria as a function of haplotypes in two 
distinct types of malaria infections: (i) incident infections where none of the haplotypes 
in the infection were previously observed in the participant’s most recent DBS or (ii) 
persistent infections where at least one haplotype persisted between consecutive DBS 
collections, excluding infections where participants had a symptomatic infection, were 
prescribed antimalarials, and had another infection with persistent haplotypes within 30 
days of the initial infection. 
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Comparing Odds of Symptomatic Malaria Among Incident Infections 
We first assessed the odds of symptomatic malaria across incident infections. 
We conducted a multi-level logistic regression comparing the odds of having a 
symptomatic compared to an asymptomatic infection across people infected with (i) only 
new haplotypes; (ii) new and recurrent haplotypes; or (iii) only recurrent haplotypes 
(Equation 5.1).  
       ln (𝑆𝑦𝑚𝑝𝑡𝑜𝑚𝑎𝑡𝑖𝑐 𝑚𝑎𝑙𝑎𝑟𝑖𝑎𝑖) = 𝛼𝑖 + 𝛽1𝐴𝑔𝑒𝑖 + 𝛽2𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑝𝑟𝑖𝑜𝑟 𝑖𝑛𝑓𝑒𝑐𝑡𝑖𝑜𝑛𝑠𝑖 +
                   𝛽3𝑇𝑟𝑎𝑛𝑠𝑚𝑖𝑠𝑠𝑖𝑜𝑛 𝑠𝑒𝑎𝑠𝑜𝑛𝑖 +  𝛽4𝑀𝑢𝑙𝑡𝑖𝑝𝑙𝑖𝑐𝑖𝑡𝑦 𝑜𝑓 𝑖𝑛𝑓𝑒𝑐𝑡𝑖𝑜𝑛𝑖 +
                   𝛽5𝐻𝑎𝑝𝑙𝑜𝑡𝑦𝑝𝑒 𝑐𝑜𝑚𝑝𝑎𝑟𝑖𝑠𝑜𝑛𝑖 +  𝜖𝑖                                                                   (5.1) 
The model included a participant-level random intercept and controlled for confounding 
covariates identified in a DAG (Figure S5.1): participant age ( 15 or > 15 years), 
number of prior malaria infections the person suffered during the study (≤ 3 or > 3 
infections), transmission season (≤ 50 or > 50 mosquitoes collected in the prior 14 days 
across study site), and multiplicity of infection (≤ 2 or > 2 haplotypes). Thresholds for 
categorization were determined by functional form assessment. Differences in model 
covariates stratified by symptomatic status were compared using the Pearson’s 2 test. 
p-values were adjusted using the Bonferroni correction for the maximum number of 
incident infections a participant suffered (N=6). 
We evaluated effect measure modification by age on the multiplicative scale by 
computing multi-level logistic regression models stratified by age category ( 15 or > 15 
years), with covariates as above. Direction of effect and 95% confidence intervals were 
compared across age-stratified models. Additionally, the log-likelihood ratio test 
compared output from an adjusted multi-level logistic regression with an interaction term 
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between age and the haplotype categories to results from the model in Equation 5.1. 
Comparing Odds of Symptomatic Malaria Among Persistent Infections 
We next evaluated the association between persistent infections and 
symptomatic malaria risk by focusing on infections harboring persistent haplotypes, 
which were defined as haplotypes also observed in testing immediately prior to the 
episode. To do this, we investigated, among only persistent infections, the relationship 
between presence of new compared to persistent haplotypes and odds of symptomatic 
malaria. First, we identified infections with persistent haplotypes and classified them 
based on presence or absence of additional haplotypes: (i) only persistent; (ii) new and 
persistent; (iii) recurrent and persistent; or (iv) new, recurrent, and persistent. Across 
these four categories, we compared the number of days since previous infection using 
the Kruskal-Wallis 2 test. 
After assessing time differences between persistent haplotype categories, we 
restricted the data set to only infections with persistent haplotypes occurring within 30 
days and computed a multi-level logistic regression. Using the same random intercept 
and covariates as Equation 5.1, the model compared the odds of developing 
symptomatic malaria across people infected with (i) mixed haplotypes (persistent 
haplotypes + new or recurrent haplotypes) or (ii) only persistent haplotypes. Differences 
in model covariates stratified by symptomatic status were investigated using the 
Pearson’s 2 test with p-values adjusted using the Bonferroni correction for 6 infections. 
Effect measure modification by age was evaluated as described above. All statistical 




The study was approved by the ethical review boards of Moi University 
(2017/36), Duke University (Pro00082000) and the University of North Carolina at 
Chapel Hill (19-1273). All study participants provided consent to participate in the study.  
Results 
Haplotype Classification and Infection Categorization 
Over 14 months, we identified 902 asymptomatic and 137 symptomatic P. 
falciparum infections (Figure 5.2A). After parasite sequencing, we obtained genotypes 
for 861 P. falciparum infections among 239 people, with a range from 1 to 14 infections 
during the study period (mean: 3.8). From these data, events meeting criteria for 
analysis as outcomes consisted of 109 pfcsp haplotypes in 622 infections (534 
asymptomatic and 88 symptomatic) across 186 people; 435 (69.9%) harbored new 
haplotypes, 320 (51.4%) harbored recurrent haplotypes, and 213 (34.2%) had 
persistent haplotypes (Figure 5.2B). A plurality of infections (27.2%) harbored only new 
haplotypes (N=169/622). Results for pfama1 are recorded in the supplement (Figure 
S5.2).  
Assessing the potential for pre-symptomatic infections across all symptomatic 
infections (N=88), persistent pfcsp haplotypes (N=37) were not as commonly found in 
symptomatic infections as new or recurrent haplotypes (N=51); however, the time 
interval in days since the last infection starting from a symptomatic infection was 
significantly shorter for infections with persistent pfcsp haplotypes (median: 12, range: 2 
to 63) than for those without persistent haplotypes (median: 39, range: 4 to 327) (p-
value <0.001 by Kruskal-Wallis 2 test) (Figure 5.3). The same relationship was seen 
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for pfama1 haplotypes (Figure S5.3). 
Analysis of Symptomaticity in Incident Infections 
We first assessed if the presence of new haplotypes influenced odds of 
symptomatic malaria among 409 incident (358 asymptomatic and 51 symptomatic) 
infections. Symptomatic infections were more likely to consist of only new haplotypes, 
occur in children, arise during the high malaria transmission season, and have a lower 
multiplicity of infection (Tables 5.1 and S5.1). Compared to infections composed of only 
recurrent pfcsp haplotypes, odds of symptomatic malaria were not significant in those 
with both new and recurrent haplotypes [OR: 0.64, 95% CI: 0.15 to 2.65] but 
significantly higher for those harboring only new haplotypes [OR: 3.24, 95% CI: 1.20 to 
8.78] (Figure 5.4A). Results were similar but not statistically significant for pfama1 
(Figure S5.4). In age-stratified models, the effect was similar in children  15 years 
[OR: 3.01, 95% CI: 1.02 to 8.84] and adults > 15 years [OR: 4.00, 95% CI: 0.44 to 
36.08], indicating, along with similarity in model fit between models with and without an 
interaction term for age (p-value = 0.996 by log-likelihood ratio test), that age did not 
modify the effect of haplotype classification on symptoms (Figure 5.4B).  
Analysis of Symptomaticity in Persistent Infections 
Persistent pfcsp haplotypes were identified in 213 infections and categorized 
into: (i) only persistent (N=57); (ii) new and persistent (N=76); (iii) recurrent and 
persistent (N=29); or (iv) new, recurrent, and persistent (N=51) (Figure 5.2B). Across all 
categories, the time interval since the previous infection ranged from 2 to 96 days 
(median: 28) (Figure 5.5A). Although we observed a cluster of infections consisting 
solely of persistent haplotypes with very small intervals, overall, the number of days 
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since previous infection did not differ between haplotype categories (p-value = 0.249 by 
Kruskal-Wallis 2 test). Results were similar for pfama1 (Figure S5.5). 
In order to test whether the acquisition of new or recurrent haplotypes affected 
the odds of symptomatic compared to asymptomatic malaria among people with a 
background of persistent parasite haplotypes, we restricted the data set to only 
persistent infections that occurred within 30 days. Meeting this 30-day criteria, we 
assessed 139 infections with at least one persistent pfcsp haplotype across 109 
asymptomatic and 30 symptomatic infections. Symptomatic infections were more likely 
to consist of only persistent haplotypes and have a lower multiplicity of infection (Tables 
5.2 and S5.2). Compared to infections with only persistent pfcsp haplotypes, the 
acquisition of additional haplotypes (either new or recurrent) was not associated with 
symptomatic disease [OR: 0.77, 95% CI: 0.21 to 2.75] (Figure 5.5B). Results were 
similar using pfama1 (Figure S5.6). Owing to small sample sizes, we could not assess 
effect measure modification of these associations by age. 
Discussion 
In a high-transmission setting in Western Kenya, incident P. falciparum infections 
composed of parasite haplotypes that were hitherto unobserved within an individual 
increased that person’s odds of symptomatic malaria. In contrast, the appearance of 
new haplotypes in a person who was already infected with persistent haplotypes was 
not associated with increased odds of symptoms. Collectively, our results are consistent 
with a model of anti-disease immunity in which genetically-distinct parasites can 
overcome immunity and cause disease in incident infections, but this ability is 
attenuated by the presence of persistent, tolerated parasites. 
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 Compared to infections with haplotypes a person has experienced previously, we 
found incident infections with only new haplotypes were associated with increased odds 
of symptomatic malaria over 3-fold. These results are consistent with the phenomena 
that partial variant-specific immunity is acquired over time to provide anti-disease 
protection, and extend the findings of prior studies that report an increased risk of 
symptomatic malaria when infected with novel haplotypes.20,86,96–99 Notably, our findings 
resulted from approaches that overcame limitations in these studies, including small 
sample sizes with brief follow-up,97–99 infrequent sampling,86,99 genotyping approaches 
with high failure rates,20 and an inability to capture multiclonal genotypes.20,86,96–99 
Specifically, genotyping approaches that use PCR-restricted fragment length 
polymorphism to detect size variants,20,86,96–99 capture only 30% of the unique clones 
present compared to amplicon deep sequencing.110 Due to this inability to capture all 
clones present in complex infections common to high-transmission areas,111 these 
approaches fail to accurately classify haplotypes as new or recurrent. Using fine-scale 
genotypes created by the more sensitive amplicon deep sequencing method,110 we 
were able to more definitively partition the distinct effects of new or recurrent haplotypes 
within incident infections. Our results, which are predicated on 14 months of follow-up of 
a diverse population with frequent sampling and high-resolution parasite genotyping, 
suggest that symptomatic malaria amongst frequently-infected residents of a high-
transmission setting is associated with the acquisition of blood-stage parasites to which 
a person has been hitherto unexposed. 
Surprisingly, this increased risk of symptomatic disease with new parasite 
haplotypes was attenuated when new haplotypes were mixed with recurrent ones. This 
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could not be attributed to the “persistence” of these recurrent haplotypes, because this 
analysis was restricted to incident infections, suggesting the acquisition of “known” (i.e. 
recurrent) parasite strains may mediate the disease-causing effects of new haplotypes; 
this could result from cross-reacting immune recognition of recurrent parasites that 
either enhances parasite clearance or attenuates immune activation,147,150 competition 
between haplotypes that reduces pathogenesis151 or alternate mechanisms. Also 
surprising, and in contrast to a prior report,20 we observed an increased risk of 
symptomatic malaria when new haplotypes were present in both adults and children. 
The ability to register this effect is likely due to the use of a more sensitive genotyping 
method that could capture diverse clones in polygenomic infections, which are more 
common in adults. The presence of this risk in adults supports an age-independent 
mechanism for this phenomenon, despite the common assumption that by reaching 
adulthood one has acquired durable immunity to diverse parasites.  
 Interestingly, in contrast to incident infections, persistent infections were not likely 
to be symptomatic when supplemented by new or recurrent parasite haplotypes. The 
presence of persistent haplotypes in persistent infections suggests a state of immune 
tolerance may be maintained and limit responses to superinfections.150 Alternately, the 
pre-existing blood-stage infection with persistent haplotypes may limit efficiency of 
establishing and maintaining super-infections, as observed in a murine model;141 this 
would be consistent with the original meaning of ‘premunition’, wherein 
contemporaneous infection confers resistance to superinfection.152 Finally, 
asymptomatic infections with persistent haplotypes could be pre-symptomatic and, thus, 
not greatly impacted by the acquisition of new or recurrent haplotypes. Regardless of 
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mechanism, these results illustrate the importance of distinguishing between recurrent 
and persistent haplotypes in incident and persistent infections, which has previously not 
been done.16,20,86,96–99 Moreover, future work could assess variability in haplotype within-
host competition,151 virulence of specific haplotypes,153 and host immune responses to 
more directly measure how new, recurrent, and persistent haplotypes affect 
symptomatic malaria risk. 
Broadly, our results highlight not only the role that incident and persistent 
infections have on reducing odds of symptomatic disease, but also the critical influence 
of parasite genetic diversity on this relationship. In population-based studies, reduced 
transmission as reflected by decreases in passively-detected cases can increase and 
shift the severity of disease,154 possibly by reduced acquisition of anti-disease immunity 
in childhood. In our study, such anti-disease immunity manifested in incident infections 
such that symptomaticity was prevented by the presence of recurrent haplotypes. 
Because these recurrent haplotypes require exposure to prior diverse infections, 
reduced exposure would increase the likelihood that incident infections are composed of 
new haplotypes and therefore likely to manifest symptoms. However, if reduced 
transmission is accompanied by reductions in parasite genetic diversity as has been 
reported in several settings,155,156 even with fewer prior infections the per-infection 
likelihood that a parasite will harbor recurrent haplotypes would remain high and thereby 
attenuate symptoms. Future studies could explore if specific haplotypes at disease-
mediating loci differentially modify the risk of malaria and thereby furnish targets for 
surveillance.      
The study had some limitations. While amplicon deep sequencing was a 
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sensitive method for identifying different malaria infections,110 it might not have captured 
all genetically-distinct infections that occurred during the study. To account for this, we 
compared results across two unlinked parasite gene targets, pfama1 and pfcsp. We did 
not observe malaria infections that participants acquired before the study; misclassifying 
a haplotype as new when it might have been present in an individual prior to the study 
would bias results towards the null. Additionally, persistent infections were possibly pre-
symptomatic. Future studies could have more frequent longitudinal sampling to 
distinguish between asymptomatic and pre-symptomatic infections at a finer scale. 
 In conclusion, these results indicate that infections harboring novel haplotypes 
increased the likelihood of symptomatic malaria in incident infections, but not when 
acquired in the presence of persistent infections. Future research could explore at the 
immunological level how the impact of new haplotypes changes the risk of symptomatic 





Table 5.1. Distribution of symptomatic status across covariates for incident 
infections with new and recurrent pfcsp haplotypes 
 
Abbreviations: IQR, interquartile range; NE, not evaluated 
# During their participation in the cohort prior to the event. 
* Low:  50 mosquitoes collected in the two weeks prior; High:  > 50 mosquitoes  








Haplotype category, N (%)   <0.001a 
    Only new 133 (37.2) 36 (70.6)  
    New and recurrent 134 (37.4) 5 (9.8)  
    Only recurrent 91 (25.4) 10 (19.6)  
Age, N (%)   0.016a 
     15 years 213 (59.5) 42 (82.4)  
    > 15 years 145 (40.5) 9 (17.6)  
Number of prior malaria infections#, N (%)   1.000a 
     3 252 (70.4) 40 (78.4)  
    > 3 106 (29.6) 11 (21.6)  
Transmission season*, N (%)   0.004a 
    Low 245 (68.4) 22 (43.1)  
    High 113 (31.6) 29 (56.9)  
Multiplicity of infection, N (%)   0.022a 
    1-2 pfcsp haplotypes 200 (55.9) 40 (78.4)  
    > 2 pfcsp haplotypes 158 (44.1) 11 (21.6)  
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Table 5.2. Distribution of symptomatic status across covariates for consecutive 
infections with persistent and new or recurrent pfcsp haplotypes 
 
Abbreviations: IQR, interquartile range; NE, not evaluated 
^ Infections with mixed types of haplotypes harbored persistent haplotypes + at least one new or 
recurrent haplotype.   
# During their participation in the cohort prior to the event. 
* Low:  50 mosquitoes collected in the two weeks prior; High:  > 50 mosquitoes  










Haplotype category, N (%)   0.002a 
    Mixed types of haplotypes^ 86 (78.9) 13 (43.3)  
    Only persistent haplotypes 23 (21.1) 17 (56.7)  
Age, N (%)   1.000a 
     15 years 76 (69.7) 23 (76.7)  
    > 15 years 33 (30.3) 7 (23.3)  
Number of prior malaria infections#, N (%)   0.801a 
     3 65 (59.6) 23 (76.7)  
    > 3 44 (40.4) 7 (23.3)  
Transmission season*, N (%)   0.755a 
    Low 70 (64.2) 14 (46.7)  
    High 39 (35.8) 16 (53.3)  
Multiplicity of infection, N (%)   <0.001a 
    1-2 pfcsp haplotypes 29 (26.6) 21 (70.0)  
    > 2 pfcsp haplotypes 80 (73.4) 9 (30.0)  
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Figure 5.1. Haplotype categorization throughout participant follow-up. 
Two hypothetical scenarios illustrate how the malaria haplotypes that participants 





Figure 5.2. Total number of P. falciparum infection types and categorization of 
pfcsp haplotypes within these infections. 
5.2A: Asymptomatic and symptomatic P. falciparum positive samples were captured 
during 14 months of sampling. Symptomatic infections were captured during as-needed 
sick visits and asymptomatic infections during monthly visits. A person’s initial infection 
is light grey. Subsequent infections for that person were used for outcome 
ascertainment (dark grey). 5.2B: Overlap of pfcsp haplotype categories across all 
symptomatic and asymptomatic P. falciparum infections (N=622). Numbers indicate the 







Figure 5.3. Comparison of time since previous infection for symptomatic malaria 
infections with or without persistent pfcsp haplotypes.  
Distribution of the number of days since previous infection across all symptomatic 
malaria infections stratified by whether or not the infection had pfcsp haplotypes persist 





Figure 5.4. Incident infections: Comparison of odds of symptomatic malaria 
between infections harboring new versus recurrent pfcsp haplotypes. 
5.4A: Multi-level logistic regression results for the odds of symptomatic malaria 
comparing (i) only new versus only recurrent and (ii) new and recurrent versus only 
recurrent pfcsp haplotypes. Dots indicate point estimate of the odds ratio, and lines the 
95% confidence intervals. 5.4B: Assessment of effect measure modification on 
symptomatic disease by age. Adjusted multi-level logistic regression models comparing 
the odds of developing symptomatic malaria between (i) only new versus only recurrent 
and (ii) new and recurrent versus only recurrent haplotypes were computed conditioned 




Figure 5.5. Persistent infections: Comparison of odds of symptomatic malaria 
between infections harboring mixed versus only persistent pfcsp haplotypes. 
5.5A: Distribution of the number of days since previous infection for malaria infections 
with persistent pfcsp haplotypes. Infections were categorized into: (i) only persistent; (ii) 
new and persistent; (iii) recurrent and persistent; and (iv) new, recurrent, and persistent. 
Asymptomatic infections were represented by circles and symptomatic ones by 
triangles. 5.5B: Adjusted multi-level logistic regression results for the odds of 
symptomatic malaria comparing consecutive infections with mixed types of haplotypes 
versus only persistent haplotypes. Dots represent odds ratios and lines the 









CHAPTER VI: GENOTYPING COGNATE PLASMODIUM FALCIPARUM IN HUMANS 





Despite sustained malaria prevention efforts, progress in malaria control has 
stalled since 2010, with 228 million malaria episodes in 2018.145 This persistence could 
result from a failure to target and mitigate infections in individuals or populations that 
disproportionally contribute to malaria transmission, so called malaria reservoirs. 
Sustained Plasmodium falciparum transmission despite case reductions could result 
from asymptomatic P. falciparum infections.9,36,43–46 Asymptomatic infections are 
defined as the presence of parasites in the blood at any density in the absence of 
malaria-like symptoms52 and typically represent either a state prior to development of 
symptoms (i.e. pre-symptomatic)52 or one in which symptoms are attenuated due to 
non-sterilizing adaptive immunity.157 Asymptomatic infections include both 
submicroscopic and microscopically patent infections which have different capacities for 
infecting mosquitoes.158 Because asymptomatic infections are sub-clinical and therefore 
often remain untreated,39 asymptomatically infected people can remain infectious to 
mosquitoes for prolonged periods and fuel onward transmission despite control 
 
1 This chapter previously appeared as an article in Nature Communications. The original citation is as 
follows: Sumner KM, Freedman E, Abel L, Obala A, Pence BW, Wesolowski A, Meshnick SR, 
Prudhomme-O’Meara W, Taylor SM. “Genotyping cognate Plasmodium falciparum in humans and 
mosquitoes to estimate onward transmission of asymptomatic infections,” Nature Communications 12 




The relative contribution of asymptomatic infections to overall malaria 
transmission is incompletely understood. Several studies have compared the 
transmission potential of asymptomatic and symptomatic P. falciparum infections to 
mosquitoes and have generally confirmed that such infections are transmissible.59–63 
However, the small sample sizes and use of experimental approaches with artificial 
membrane feeding by laboratory-reared mosquitos limit generalizability by failing to 
capture variations in human activity, vector complexity and behavior, and parasite 
biology that influence transmissibility in natural settings. Such controlled feeding studies 
are critical to understand the fundamental biology of parasite transmission, and studies 
in natural, uncontrolled settings are necessary to confidently extend these insights to 
understand how they shape disease epidemiology. It is particularly critical to understand 
the impact of these infections in complex high-transmission settings, in which 
asymptomatic infections are highly prevalent but not commonly prioritized in 
transmission-reduction efforts. Such efforts include enhanced testing, treatment, and 
prevention on either mass or focal scales, and these tools can be employed more 
efficiently and rationally with a better understanding of the relative transmissibility of 
asymptomatic P. falciparum infections. 
We investigated the contribution of asymptomatic P. falciparum infections to 
successful mosquito infection in a 14-month longitudinal cohort of 239 people in 
Western Kenya, a hyperendemic area where asymptomatic infections are common.6,8 In 
these households, we collected cognate infections in both people and indoor-resting 
Anopheline mosquitoes, under the premise that, owing to the endophilic and 
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endophagic preferences for feeding by the principal vectors Anopheles gambiae and A. 
funestus, household transmission would be both measurable and substantial. Building 
upon previous studies, our approach combines empirical data collection of naturally fed 
mosquitoes, parasite genotyping using amplicon deep sequencing, and probabilistic 
modelling to estimate the transmissibility from people to mosquitoes of asymptomatic 
relative to symptomatic P. falciparum infections. We hypothesized that, compared to 
symptomatic infections, asymptomatic infections would be a larger source of infected 
mosquitoes.  
Methods 
Study Population and Data Collection 
A longitudinal cohort of households across three villages (Kinesamo, Maruti, and 
Sitabicha) in Bungoma county, Kenya was established in June 2017 and followed until 
July 2018. The three villages were selected based on their high malaria prevalence in a 
previous cross-sectional study.32 All household members in participating households 
over the age of 1 year were offered enrollment. Sample collection details have been 
reported.127 For each participant, demographic and behavioral questionnaires were 
administered and dried blood spot (DBS) samples collected every month. The DBS 
were tested for P. falciparum parasites using real-time PCR post-hoc (see below), and 
therefore parasites detected in asymptomatic people were not treated.  Participants 
contacted the study team at any time when experiencing symptoms consistent with 
malaria, at which time they were tested for malaria using a rapid diagnostic test (RDT) 
(Carestart Malaria HRP2 Pf from Accessbio)115 and, if positive, treated with Artemether-
Lumefantrine. DBS were also collected at the time of RDT testing. One morning each 
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week, indoor resting mosquitoes were collected from participant households using 
vacuum aspiration with Prokopacks.116 From these collections, female Anopheles 
mosquitoes were identified morphologically and transected to separate the abdomen 
from the head and thorax.  
Participant and Mosquito Sample Processing  
Genomic DNA (gDNA) was extracted from mosquito abdomens and DBS 
samples using a Chelex-100 protocol.128 gDNA from each DBS and mosquito was 
tested in duplicate using a duplex TaqMan real-time PCR (qPCR) assay targeting the P. 
falciparum pfr364 motif and the human -tubulin gene.129 Samples were defined as P. 
falciparum-positive if: (i) both replicates amplified P. falciparum and both Ct values were 
< 40 or (ii) 1 replicate amplified P. falciparum and Ct value was < 38. P. falciparum-
positive samples were genotyped across variable segments of genes encoding the 
apical membrane antigen-1 (pfama1) and circumsporozoite protein (pfcsp) as previously 
described,148 with some additional steps taken for low parasite density samples (see 
Supplementary Information). Ultimately, dual-indexed libraries were prepared for both 
gene targets, then pooled and sequenced on an Illumina MiSeq platform.117  
Sequencing reads were filtered based on read length and Phred quality scores 
and mapped to the 3D7 reference sequences for pfama1 and pfcsp.118–122,148 We 
performed haplotype inference on mapped reads using DADA2 (version 1.8) as 
implemented in R (version 3.6.1).123,126 These putative haplotypes were then further 
filtered in order to mitigate the risk of false discovery by removing haplotypes from a 
sample that met any of the following criteria: (i) supported by < 250 reads within the 
sample; (ii) supported by < 3% of the sample’s total read depth; (iii) deviation from the 
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expected nucleotide length of 300 for pfama1 or 288 for pfcsp; or (iv) a minority 
haplotype distinguished by a one single-nucleotide polymorphism (SNP) difference from 
another haplotype within the sample that had a read depth > 8 times the read depth of 
the minority haplotype.124 Finally, we removed a haplotype from the overall population if 
it was defined by a single variant position that was only variable within that haplotype 
(see Supplementary Information, Figures S6.1-S6.4). All genetic sequences are 
available through the National Center for Biotechnology Information GenBank 
(BioProject Number PRJNA646940).  
Exposure Assessment 
The main exposure was the classification of an infection as asymptomatic or 
symptomatic. We defined an asymptomatic infection as a P. falciparum infection 
detected by qPCR during active case detection in a participant lacking symptoms. We 
defined a symptomatic infection as a P. falciparum infection detected by both RDT and 
qPCR during passive case detection in a participant with at least one malaria-like 
symptom. To reduce potential for exposure misclassification, individual asymptomatic 
and symptomatic infections were excluded from the analysis if they occurred within 14 
days of taking study-prescribed antimalarials for a symptomatic infection.  
Within-participant Modeling of Transmissibility 
To assess the likelihood of transmission by symptomatic status, we compared 
the proportion of mosquitoes that shared a haplotype between a participant’s 
asymptomatic and symptomatic infections. To do so, we included only participants that 
had at least one asymptomatic and one symptomatic infection. We then paired each 
participant’s infection events with all mosquitoes that were collected within 3 kilometers 
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as well as between 7 days prior to and 14 days following the participant infection, in 
order to constrain the search space for plausible transmission events to within time and 
distance parameters that are consistent with parasite and mosquito biology. For each 
infection, we computed the proportion of participant-mosquito pairings that shared at 
least one haplotype, and did so separately using either pfcsp or pfama1 haplotypes. 
We assessed the statistical significance of differences in these proportions 
between asymptomatic and symptomatic infections using a multi-level logistic 
regression model (Equation 6.1): 
                ln (𝑇𝑟𝑎𝑛𝑠𝑚𝑖𝑠𝑠𝑖𝑜𝑛 𝑒𝑣𝑒𝑛𝑡𝑖𝑗) = 𝛼𝑖 + 𝛼𝑗 + 𝛽1𝐴𝑠𝑦𝑚𝑝𝑡𝑜𝑚𝑎𝑡𝑖𝑐 𝑖𝑛𝑓𝑒𝑐𝑡𝑖𝑜𝑛𝑖𝑗 +
                         𝛽2𝑃𝑎𝑟𝑎𝑠𝑖𝑡𝑒 𝑑𝑒𝑛𝑠𝑖𝑡𝑦𝑖𝑗 +  𝛽3𝑀𝑜𝑠𝑞𝑢𝑖𝑡𝑜 𝑎𝑏𝑢𝑛𝑑𝑎𝑛𝑐𝑒𝑖𝑗 +  𝜖𝑖𝑗                         (6.1) 
This model included a random intercept at the participant level (𝛼𝑖) and one at the 
household level (𝛼𝑗) to account for repeated measures of participants clustered in 
households throughout the study. The model included covariates for parasite density (in 
parasites/L in the participant samples) and mosquito abundance (expressed as the 
total number of female Anopheles mosquitoes collected within the week following the 
participant infection as <75 mosquitoes or 75 mosquitoes). The cutoffs for the number 
of mosquitoes chosen to represent mosquito abundance was determined by a functional 
form assessment and known malaria seasonality. 
Probabilistic Modeling of Transmission Across All Participants 
For a more comprehensive measure of transmission across all participants, we 
created a probabilistic model to estimate the probability that a shared haplotype 
between a participant and a mosquito represented a P. falciparum transmission event 
[𝑃(𝑇𝐸𝑎𝑙𝑙)]. 𝑃(𝑇𝐸𝑎𝑙𝑙) was estimated for the pairing of each infected participant with an 
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infected mosquito on the basis of three distinct features: (i) the time interval between the 
participant’s infection and mosquito collection [𝑃(𝑇𝐸𝑡)], (ii) the distance between the 
household of the participant and the household where the mosquito was collected 
[𝑃(𝑇𝐸𝑑)], and (iii) the prevalence and number of parasite haplotypes shared [𝑃(𝑇𝐸ℎ)]. 
For each pairing, we calculated these terms and then multiplied them to estimate 
𝑃(𝑇𝐸𝑎𝑙𝑙). 𝑃(𝑇𝐸𝑎𝑙𝑙) values were computed independently using pfama1 or pfcsp 
haplotypes.  
Probability of Participant-to-mosquito Transmission Over Time 
 𝑃(𝑇𝐸𝑡) was defined as the probability of participant-to-mosquito parasite 
transmission as a function of the time interval between specimen collections. The 
rationale for this term was that participant-to-mosquito transmission could only occur 
within a certain time window based on the mosquito lifespan and parasite life cycle.37,159 
𝑃(𝑇𝐸𝑡) was assigned as 1 if a mosquito was collected within a 21-day window of the 
participant infection, spanning 7 days before the participant infection and 14 days after 
(Figure S6.5). This range only allowed participant-to-mosquito malaria transmission to 
be captured, following infections from participants to mosquito abdomens. If the 
mosquito was collected outside of this window, 𝑃(𝑇𝐸𝑡) was set to 0. A sensitivity 
analysis was conducted to assess how differences in the time window chosen affected 
results, expanding the time window to allow mosquitoes to be collected up to 30 days 
after the participant’s infection (Figure S6.6). 
Probability of Participant-to-mosquito Transmission Over Distance  
𝑃(𝑇𝐸𝑑) was defined as the probability of participant-to-mosquito parasite 
transmission as a function of Euclidean distance between specimen collections. This 
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term was included to restrict participant-mosquito pairs to only be considered as a 
possible transmission event within a reasonable distance for a mosquito to fly. 𝑃(𝑇𝐸𝑑) 
was calculated using a modified negative exponential distribution previously observed in 
a study tracking Anopheles mosquito movement (Equation 6.2; Figure S6.7):160  
                                                         (6.2) 
For example, by 0.66 kilometers from the participant, which was the maximum distance 
blood fed Anopheles mosquitoes were observed to fly in a Kilifi study,161 the probability 
of transmission was already low (14%) and at 3 kilometers it had dropped to 0% 
entirely. A sensitivity analysis was conducted to evaluate how changing the distance 
between specimen collection to allow specimen collection at a distance greater than 3 
kilometers influenced results (Figure S6.8). We also compared the number of pfcsp 
haplotypes shared within 3 kilometers compared to at a distance of greater than 3 
kilometers (Figure S6.9). 
Probability of Participant-to-mosquito Transmission Over Haplotypes  
𝑃(𝑇𝐸ℎ) was defined as the probability that a shared haplotype represented a 
participant-to-mosquito parasite transmission as a function of the number of shared 
haplotypes and the population prevalence of each shared haplotype. The premise of the 
calculation of 𝑃(𝑇𝐸ℎ) was that the probability that haplotype sharing represented a 
transmission event increased with a higher number of haplotypes shared as well as the 
rarity of those haplotypes across the study population. 𝑃(𝑇𝐸ℎ) was calculated 
independently for pfama1 and pfcsp haplotypes using Equation 6.3: 
                                                    (6.3) 
𝑃(𝑇𝐸𝑑) =  𝑒
−3𝑑  











1. 𝑠 indicates the number of haplotypes of a gene target (pfcsp or pfama1) that are 
shared between components of the pair;  
2. 𝑃𝑜𝑝𝑃𝑟𝑒𝑣 indicates the prevalence of the haplotype across the entire study 
population, calculated by dividing the number of samples with that haplotype by 
the total number of samples in the study. 𝑃𝑜𝑝𝑃𝑟𝑒𝑣 is calculated from 1 to 𝑠, 
where 𝑠 is the total number of shared haplotypes between the participant and 
mosquito pair. 𝑃𝑜𝑝𝑃𝑟𝑒𝑣 for each haplotype is rescaled by taking the cubed root, 
as it is highly right skewed; and 
3.  𝑀𝑂𝐼𝑖  is the participant’s multiplicity of infection (MOI), represented by the 
number of unique gene haplotypes observed in the participant’s infection (𝑖). 
We applied the term (
𝑠
𝑀𝑂𝐼𝑖
) in order to mitigate the risk of biasing 𝑃(𝑇𝐸ℎ) towards larger 
values in participants with high MOI values. If no haplotypes were shared between the 
participant and mosquito pair, 𝑃(𝑇𝐸ℎ) = 0. 𝑃(𝑇𝐸ℎ) was calculated independently for 
pfcsp and pfama1. A sensitivity analysis was conducted comparing 𝑃(𝑇𝐸ℎ) calculated 
independently for each gene target to 𝑃(𝑇𝐸ℎ) calculated using both gene targets 
(Figure S6.10). 
Probability of Participant-to-mosquito Transmission Over All Variables 
Individual terms for 𝑃(𝑇𝐸𝑡), 𝑃(𝑇𝐸𝑑), and 𝑃(𝑇𝐸ℎ) were combined into a final 
estimate of the probability of transmission [𝑃(𝑇𝐸𝑎𝑙𝑙)]. For participant-mosquito pairs that 
had probability values > 0 of 𝑃(𝑇𝐸𝑡), 𝑃(𝑇𝐸𝑑), and 𝑃(𝑇𝐸ℎ), 𝑃(𝑇𝐸𝑎𝑙𝑙) was calculated using 
Equation 6.4: 
                                             𝑃(𝑇𝐸𝑎𝑙𝑙) = 𝑃(𝑇𝐸𝑡) ∗ 𝑃(𝑇𝐸𝑑) ∗ 𝑃(𝑇𝐸ℎ)                             (6.4) 
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If 𝑃(𝑇𝐸𝑡) > 0 and 𝑃(𝑇𝐸𝑑) > 0 but 𝑃(𝑇𝐸ℎ) = 0, 𝑃(𝑇𝐸𝑎𝑙𝑙) = 0. 𝑃(𝑇𝐸𝑡), 𝑃(𝑇𝐸𝑑), and 𝑃(𝑇𝐸ℎ) 
were rescaled to the range 0 to 1 to be comparable when multiplying. 
Statistical Analysis  
To estimate the probability of a participant-to-mosquito transmission event using 
the probabilistic method for participant-to-mosquito transmission [𝑃(𝑇𝐸𝑎𝑙𝑙)] across time, 
distance, and the haplotypes shared, we compared values between participants with 
asymptomatic and symptomatic infections using a multi-level logistic regression model 
(Equation 6.5).  
       ln (𝑇𝑟𝑎𝑛𝑠𝑚𝑖𝑠𝑠𝑖𝑜𝑛 𝑒𝑣𝑒𝑛𝑡𝑖𝑗) = 𝛼𝑖 + 𝛼𝑗 + 𝛽1𝐴𝑠𝑦𝑚𝑝𝑡𝑜𝑚𝑎𝑡𝑖𝑐 𝑖𝑛𝑓𝑒𝑐𝑡𝑖𝑜𝑛𝑖𝑗 +
𝛽2𝑃𝑎𝑟𝑎𝑠𝑖𝑡𝑒 𝑑𝑒𝑛𝑠𝑖𝑡𝑦𝑖𝑗 +  𝛽3𝐴𝑔𝑒5𝑡𝑜15𝑖𝑗 + 𝛽4𝐴𝑔𝑒15𝑜𝑣𝑒𝑟𝑖𝑗 + 𝛽5𝑀𝑜𝑠𝑞𝑢𝑖𝑡𝑜 𝑎𝑏𝑢𝑛𝑑𝑎𝑛𝑐𝑒𝑖𝑗 +
                               𝛽6𝐾𝑖𝑛𝑒𝑠𝑎𝑚𝑜 𝑣𝑖𝑙𝑙𝑎𝑔𝑒 + 𝛽7𝑆𝑖𝑡𝑎𝑏𝑖𝑐ℎ𝑎 𝑣𝑖𝑙𝑙𝑎𝑔𝑒 +  𝜖𝑖𝑗                               (6.5) 
We included a random intercept at the participant level (𝑖) to account for repeated 
measures for participants who experienced multiple malaria infections (asymptomatic or 
symptomatic) throughout the study. To consider different transmission intensities 
between households, we included a random intercept at the household level (𝑗). We 
controlled for confounding covariates that we identified in a DAG (Figure S6.11) and 
performed functional form assessments on continuous variables prior to inclusion (See 
Supplementary Information, Tables S6.3-S6.5). The final model included covariates 
for village, parasite density in the participant samples in parasites/L (linear), participant 
age at study enrollment (categorized: <5 years, 5-15 years, >15 years), and mosquito 
abundance (expressed as the total number of female Anopheles mosquitoes collected 
within the week following the participant infection as <75 mosquitoes or 75 
mosquitoes). To reduce skew for the multi-level model, parasite density was centered 
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and rescaled to have a mean of 0. 
Prior to modeling, differences in model covariates across symptomatic status 
were assessed using the Wilcoxon Rank Sum test with continuity correction for 
continuous variables and the Pearson’s 2 test for categorical variables. Differences in 
MOI across sample types were calculated using the Pairwise Wilcoxon Rank Sum test 
with the Bonferroni correction for multiple comparisons. All p-values obtained from the 
bivariate tests were adjusted using the Bonferroni correction to account for repeated 
measures across participants of up to 14 infections, which was the maximum number of 
infections observed in any participant during study follow-up. 
We conducted a sensitivity analysis of different coding choices for the 
probabilistic combination of time, distance, and haplotypes [𝑃(𝑇𝐸𝑎𝑙𝑙)]. We re-computed 
the logistic regression model specified above testing variable cutoffs for the binary 
coding of the outcome variables. Cutoffs for what was considered a participant-to-
mosquito malaria transmission ranged from 0.00 to 0.55 due to sparse data restrictions 
above 0.55. The model contained the same covariates and random effects as the model 
in Equation 6.5.  
Contribution to Infectious Reservoir of Asymptomatic Infections 
The contribution to the infectious reservoir made by asymptomatic infections was 
calculated using the odds ratio estimate obtained from the probabilistic method for 
participant-to-mosquito transmission [𝑃(𝑇𝐸𝑎𝑙𝑙)] across time, distance, and the 
haplotypes shared. The odds ratio for the binary coding of 𝑃(𝑇𝐸𝑎𝑙𝑙) was used, where 
any value of 𝑃(𝑇𝐸𝑎𝑙𝑙) indicated a participant-to-mosquito transmission event. The 




                                                                     𝐶𝑎𝑡 =
𝑃𝑎𝑡𝐼𝑎
𝑃𝑎𝑡𝐼𝑎+𝑃𝑠𝑡𝐼𝑠
∗ (100)                                          (6.6) 
where:  
1. 𝑃𝑎𝑡 represents the proportion of all infections that were asymptomatic (𝑎) during 
each month (𝑡) of follow-up;  
2. 𝑃𝑠𝑡 represents the proportion of all infections that were symptomatic (𝑠) during 
each month (𝑡) of follow-up; 
3. 𝐼𝑎 indicates the likelihood a mosquito was infected by someone with an 
asymptomatic (𝑎) infection. 𝐼𝑎 was calculated using the odds ratio obtained from 
the multi-level logistic regression model that estimated the probability of 




random effects and covariates were previously described in Equation 6.5. 𝐼𝑎 did 
not vary across months; and 
4. 𝐼𝑠 represents the likelihood a mosquito was infected by someone with a 
symptomatic (𝑠) infection. 𝐼𝑠 was calculate as follows: 𝐼𝑠 = 1 − 𝐼𝑎. 𝐼𝑠 did not vary 
across months. 
A cumulative value of 𝐶𝑎𝑡 was calculated across the entire follow-up period and 
represented by 𝐶𝑎. The upper and lower limits of the 95% confidence interval for 
𝐶𝑎 were calculated using the upper and lower limits for the 95% confidence interval from 
the estimated odds ratio. All statistical analyses were performed using R (version 
3.6.1).126 
Ethical Considerations 
All adult participants provided written informed consent prior to participation. 
Participants between the ages of 1 and 18 years old were included if their parent or 
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legal guardian provided written informed consent. Verbal assent was also obtained from 
children between 8 and 18 years. The study was approved by the ethical review boards 
of Moi University (2017/36), Duke University (Pro00082000) and the University of North 
Carolina at Chapel Hill (19-1273).  
Results 
From June 2017, we enrolled 268 participants across 3 villages in Bungoma 
County, Kenya, in the cohort study; after excluding participants with either zero P. 
falciparum infections or less than 2 months of follow-up, the analysis data set consisted 
of 239 participants across 38 households who were visited monthly for active case 
detection of asymptomatic infections and as-needed for passive case detection of 
symptomatic infections. In these participants across 14 months, we recorded 137 
symptomatic P. falciparum infections during 501 sick visits and 902 asymptomatic P. 
falciparum infections during 2312 routine visits (Figure 6.1). From their households, we 
collected 1494 female Anopheles mosquitoes; of 1450 mosquito abdomens with gDNA 
available, we identified 203 P. falciparum-positive mosquitoes. 
These 1242 real-time PCR-positive P. falciparum infections (N=902 
asymptomatic infections, N=137 symptomatic infections, and N=203 infected mosquito 
abdomens) were genotyped for the P. falciparum parasite genes encoding apical 
membrane antigen-1 (pfama1) and circumsporozoite protein (pfcsp) using PCR 
amplification, amplicon deep sequencing, and a validated haplotype inference program 
with strict quality-filtering criteria.123 Pfcsp and pfama1 were selected owing not to 
phenotypes associated with their protein products but rather to their sequence diversity, 
which enables capture of diverse parasite strains and matching strains between 
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hosts.148 Results for pfama1 haplotypes are reported in the supplement. For pfcsp, we 
obtained analyzable haplotypes that passed our custom quality filtering for 1046 
samples (84.2%), across which we identified 229 unique pfcsp haplotypes. These 
haplotypes harbored variants at 72 nucleotide positions in the sequenced segment of 
pfcsp; variants at 37 (51.4%) of these positions were previously reported (Figure 
S6.2).162–164 Many haplotypes were observed across all three sample types, but some 
haplotypes were private to asymptomatic infections, symptomatic infections or 
mosquitoes (Figures 6.2, S6.12). Between sample types, the median pfcsp multiplicity 
of infection (MOI) was higher for mosquitoes (6, Interquartile range [IQR]: 4 to 9) 
compared to either symptomatic infections (1, IQR: 1 to 3, p-value < 0.001 by Pairwise 
Wilcoxon Rank Sum Test) or asymptomatic infections (3, IQR: 1 to 7, p-value < 0.001) 
(Figure 6.2). 
We used these P. falciparum haplotypes as identifiers by which to estimate 
parasite transmission from people to mosquitoes by computing pairwise metrics of 
parasite haplotype sharing between infected participants and mosquitoes. We first 
analyzed a subset of 65 participants who suffered both asymptomatic and symptomatic 
infections, from whom we paired all 225 infected events (N=143 asymptomatic and 
N=82 symptomatic infections) with infected mosquitoes that were collected: (i) between 
7 days before and 14 days after the event, and (ii) within 3 kilometers of the participant’s 
household. This yielded 1565 participant-mosquito pairs for the 225 events; this subset 
of participants and events was similar to the overall population (Table S6.1). For each 
event, we computed the proportion of participant-mosquito pairings in which at least 1 
pfcsp haplotype was shared between the mosquito and the participant. In a multi-level 
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logistic regression model controlling for parasite density and mosquito abundance, 
compared to their symptomatic infections, their asymptomatic infections had higher 
odds of sharing a parasite haplotype with infected mosquitoes [OR: 2.56, 95% CI: 1.36 
to 4.81] (Figure 6.3). Results were similar but not statistically significant in parallel 
analyses using pfama1 [OR: 1.30, 95% CI: 0.63 to 2.69] (Figures S6.13-S6.14), 
indicating that, compared to when the individuals suffered symptomatic infections, their 
asymptomatic infections were more likely to result in successful parasite transmission to 
mosquito vectors.  
In order to more comprehensively analyze transmission across all participants 
irrespective of their infection counts, we extended our assessment of transmission using 
pairings of all infections in participants and mosquitoes using a probabilistic model of 
transmission. Across all samples over 14 months, there were 159,285 potential pairings 
of infected participants and mosquitoes, and after applying the aforementioned temporal 
and geographic distance constraints to these pairings to remove those with implausible 
transmission potential (Figure 6.4), the final analysis data set consisted of 3727 
participant-mosquito pairs. These comprised 198 participants and 182 mosquitoes that 
were drawn from 37 households across all 3 villages. Among these 3727 pairings, 
mosquitoes paired with asymptomatic participants (N=3012) outnumbered those paired 
with symptomatic participants (N=715). Compared to those including asymptomatic 
infections, pairings including symptomatic infections had higher parasite densities (p-
value < 0.001 by Wilcoxon Rank Sum test), were more likely to occur in a participant 
under 5 or over 15 (p-value < 0.001 by Pearson’s 2 test) (Tables 6.1 and S6.2) and 
typically occurred during periods with larger mosquito abundance (p-value < 0.001 by 
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Pearson’s 2 test). Across the all pairings, the median number of haplotypes shared 
within a participant-mosquito pair was 1 (range: 0 to 8, IQR: 0 to 2) for asymptomatic 
and 0 (range: 0 to 7, IQR: 0 to 1) for symptomatic infections.  
For each of these 3727 pairings, we computed the probability that a shared 
haplotype between a participant and mosquito represented a transmission event 
[𝑃(𝑇𝐸𝑎𝑙𝑙)] as a function of three indices: (i) temporal distance [𝑃(𝑇𝐸𝑡)], (ii) geographic 
distance [𝑃(𝑇𝐸𝑑)], and (iii) the prevalence and quantity of shared haplotypes between 
samples [𝑃(𝑇𝐸ℎ)] (Figure 6.4). The rationale for this approach was to assign a 
probability to each pair that reflected the level of confidence that the pair represented a 
participant-to-mosquito transmission event. The probability increased for pairs that were 
closer in space or time and for those which shared a higher number of haplotypes or 
haplotypes that were comparatively rare across samples. We aggregated all three terms 
into a compound estimate of a probable transmission event [𝑃(𝑇𝐸𝑎𝑙𝑙)]; across all 
pairings (N=3727), the median 𝑃(𝑇𝐸𝑎𝑙𝑙), was 0.05 (IQR: 0.00 to 0.15), and among only 
those pairings with at least 1 shared haplotype (N=2278), the median 𝑃(𝑇𝐸𝑎𝑙𝑙) was 0.12 
(IQR: 0.06 to 0.21). 𝑃(𝑇𝐸𝑎𝑙𝑙) represented a relative likelihood that a human and 
mosquito pair that shared parasite haplotypes represented a transmission event and 
should be interpreted relative to other 𝑃(𝑇𝐸𝑎𝑙𝑙) values.  
We compared our estimates of transmission for each pairing between those with 
asymptomatic and symptomatic infections using a multi-level logistic regression 
on 𝑃(𝑇𝐸𝑎𝑙𝑙), controlling for parasite density, participant age, mosquito abundance, and 
village. Using pfcsp haplotypes for haplotype indices, compared to symptomatic 
infections, asymptomatic infections had 50% higher odds of being matched to a 
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mosquito infection [OR: 1.50, 95% CI: 1.07 to 2.10] (Figure 6.5). In parallel analyses 
using pfama1, we observed a similar increase in the odds of transmission to mosquitoes 
from asymptomatic compared to symptomatic infections [OR: 1.22, 95% CI: 0.82 to 
1.82] (Figure S6.15). We re-computed regression models after dichotomizing our 
estimated 𝑃(𝑇𝐸𝑎𝑙𝑙) values at various cutoffs from 0.00 to 0.55, reflecting the range of 
𝑃(𝑇𝐸𝑎𝑙𝑙) values and increasing stringency for defining a transmission event (Figure 
6.5). Across this broad range of 𝑃(𝑇𝐸𝑎𝑙𝑙) definitions, asymptomatic infections had 
consistently higher odds of onward parasite transmission. When we defined a 
transmission event as any non-zero 𝑃(𝑇𝐸𝑎𝑙𝑙) value, reflecting sharing between 
participant and mosquito of any number and quality of haplotypes, compared to 
symptomatic infections, asymptomatic infections more than doubled the odds of 
transmission to a mosquito [OR: 2.66, 95% CI: 2.05 to 3.47].  
Finally, we used this measurement to estimate the contribution of each type of 
infection to onward transmission across our population as a function of the monthly 
proportion of all infections that were asymptomatic, which varied from 73.4% to 97.4% 
between months. Using these, we estimated that monthly contributions to mosquito 
infections by asymptomatic infections varied from 88.0% to 99.0% (Figure 6.5), and 
averaged across all months in our high and perennial transmission setting, 
asymptomatic infections were the source of 94.6% (95% CI: 93.1 to 95.8%) of mosquito 
infections.  
Discussion  
In this longitudinal epidemiological and entomological cohort in Western Kenya, 
we investigated the relative contributions to onward P. falciparum transmission of 
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asymptomatic compared to symptomatic P. falciparum infections. To do so, we 
analyzed parasite haplotypes in people and mosquitoes using a probabilistic model to 
directly estimate participant-to-mosquito malaria transmission. We report that, 
compared to symptomatic people, those with asymptomatic infections had more than 
double the odds of transmission to mosquitoes. Owing to this as well as the high 
prevalence of asymptomatic infections, we estimated that asymptomatic infections were 
the source of nearly all P. falciparum parasites infecting mosquitoes. Our findings 
provide an explicit rationale to target asymptomatic P. falciparum infections as a 
component of transmission-reducing programs. 
Across 14 months of observation in a high-transmission setting, asymptomatic P. 
falciparum infections were the major source of onward malaria transmission. 
Specifically, relative to symptomatic infections, asymptomatic infections had 2.66-fold 
odds of probable malaria transmission to mosquitoes. Our findings are consistent with 
results from smaller studies, which suggested that asymptomatic infections were more 
likely to transmit to mosquitoes than symptomatic infections.61,62 Those studies used 
experimental feeding on infected blood by laboratory-reared mosquitoes to measure 
transmission, and therefore could not capture variance in the feeding behaviors of 
vectors112 or the natural trajectories of infections.113 Our findings build upon these 
previous studies by capturing participant-to-mosquito transmission longitudinally, in a 
larger study population, and in a natural setting with mosquitoes collected within 
participants’ households. Notably, we also observed this positive association between 
asymptomatic infections and transmission among the overall cohort using the alternate, 
unlinked parasite genotyping locus of pfama1 as well as among a subset of participants 
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who suffered both asymptomatic and symptomatic infections during the study period. 
Although our study does not enable the identification of a clear mechanism for this 
association, a lack of symptoms may allow a longer duration of infection, and thereby 
enable both the development of gametocytes as well as more opportunities to be bitten 
by and transmit malaria to mosquitoes.39 
Our approach used probabilistic modelling of genotypes captured by amplicon 
deep sequencing to estimate P. falciparum transmission. Prior studies of participant-to-
mosquito malaria transmission using alternate approaches59–63 have incompletely 
captured the complexity of natural systems, which limits their generalizability. Mosquito 
feeding experiments employing either direct skin or membrane feeding fail to represent 
numerous participant-, mosquito-, and parasite-related factors that are critical to 
transmission. These critical factors include variance among mosquito vectors in biting 
preferences,165 behaviors,112 and success;166 among parasites in replication rates113 
and gametocyte production;167 and among participants in exposure to vectors168 and 
care-seeking behavior.169 Similarly, this complexity also confounds the use of 
gametocyte prevalence or density as a proxy for transmission,170 which may more 
precisely define which infections can rather than do transmit. Other studies have used 
modelling approaches to estimate how transmission dynamics could change in a more 
realistic setting, finding that submicroscopic infections are a large source of malaria 
spread;65,136 however, the studies did not examine how transmission differed by 
symptomaticity.  
This approach to measure participant-to-mosquito transmission offers a scalable 
tool that can be adapted to diverse settings. Consistent with prior reports from high-
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transmission settings,148,171–174 we found high diversity of pfama1 and pfcsp haplotypes 
in our study site, likely the result of strong balancing selection on these loci exerted by 
immune pressure. This large number of unique haplotypes allowed us to both identify 
matches between participant-mosquito pairs as well as weight the relevance of those 
matches for potential transmission events based on the quantity and rarity of shared 
haplotypes. Importantly, amplicon deep sequencing enabled this approach with its 
technical ability to capture minority variants within mixed infections110 and scalability in a 
large field study.175 More precise estimations of individual transmission events as well 
as mapping of transmission chains, may require novel approaches using higher-
dimensional genotyping combined with analytic models that resolve polygenomic 
infections. Our results highlight how integrated genetic and computational approaches 
can be implemented in large field studies to leverage parasite genetic diversity for 
investigating fundamental features of parasite epidemiology. 
Using this approach, we observed that the median number of pfcsp haplotypes 
(or MOI) was much higher in mosquito infections (6) than in asymptomatic (3) or 
symptomatic (1) human infections (Figure 6.2). This high median MOI in mosquito 
abdomens is surprising given that wild-caught176 and membrane-fed177 Anopheline 
mosquitoes typically have < 5 oocysts, suggesting that the high amount of genetic 
diversity that we observed was likely harbored by a very small number of oocysts in the 
collected mosquitoes. This could have resulted from the transmission to mosquitoes of 
cryptic haplotypes that were undetectable in asexual human infections, as has been 
reported with both P. falciparum and P. vivax,178 although both sample types were 
processed analogously and were subjected to identical haplotype quality filtering 
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criteria. On a related note, partial immune recognition of expressed circumsporozoite 
protein or apical membrane antigen-1 variants, which are expressed in the liver or blood 
stage respectively, may have served to differentially limit the densities of certain 
variants below the limits of detection in human infections while allowing passage to and 
propagation in mosquitoes. Finally, given evidence that Anopheles gambiae can take 
multiple bloodmeals per gonotropic cycle,179–181 and that this behavior may be 
enhanced by an existing sporozoite infection of the mosquito,182 these oocysts may 
represent an accumulation of parasites acquired over multiple feedings on multiple days 
from multiple infected humans, which collectively would enhance the diversification of 
midgut parasites.  
The finding that asymptomatic P. falciparum infections are the primary source of 
infections in mosquito vectors provides an explicit rationale to target these infections in 
order to reduce transmission in highly-endemic settings. Across sub-Saharan Africa 
asymptomatic P. falciparum infections are highly prevalent:49,50,52,183 one meta-analysis 
estimated a continent-wide prevalence in 2015 of 24% among just children aged 2 to 10 
years.35 Asymptomatic infections have been targeted in prior studies either by testing 
defined geographic or demographic groups (i.e. active case detection) or by foregoing 
testing and implementing mass-drug administration (MDA) of antimalarials.184 Both 
active case detection and MDA have proven effective or been implemented in low-
transmission, pre-elimination settings, where they have been recommended as 
interventions to accelerate progress to elimination.185 In contrast, high-transmission 
settings like ours rely on bed net use, access to care, use of rapid diagnostics, and 
treatment with artemisinin-based combination therapies (ACT) for control.145 Despite the 
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adoption of all of these interventions in our study site, asymptomatic infections remained 
the major source of mosquito infections, suggesting the need for enhanced 
interventions. The efficacy of such interventions in high-transmission settings on the 
asymptomatic reservoir specifically – and on transmission reduction more generally – 
may be feasibly testable with novel tools to estimate transmission using serologic186 or 
parasite genetic155 measures.  
Our study had several limitations. Symptomatic infections were quickly 
diagnosed and treated with effective therapy under our protocol which likely reduced the 
duration of these infections and therefore limited their transmission potential. This 
access to diagnosis and treatment is higher than is generally available across sub-
Saharan Africa,145 though recent reports indicate gradual improvement in quality clinical 
management.187 Conversely, we may have under-detected asymptomatic infections and 
therefore over-represented symptomatic infections, owing either to the sparse monthly 
sampling for asymptomatic infections or the inability to capture transmission from 
symptomatic infections during their asymptomatic or pre-symptomatic phase. We expect 
that this would serve mainly to bias our analyses towards the null by providing relatively 
more opportunities for symptomatic infections to match to mosquitoes. Similarly, 
mosquito sampling was necessarily sparser than human sampling, precluding absolute 
measurement of all transmission events but allowing for relative estimations to onward 
transmission. We had no direct measurement of gametocytes due to the types of 
sample collection, precluding a direct analysis of their participation in transmission; 
however, we adjusted models for asexual parasite density, which has been suggested 
as a proxy for gametocyte density.158 We only measured transmission directly within 
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households, and cannot capture events occurring in other settings; this limitation is 
mitigated by the known nocturnal feeding preference of local vectors. Finally, many 
infections in participants and mosquitoes had low parasite densities, which increases 
the risk of haplotype false discovery.124 To mitigate this risk, we enforced stringent 
haplotype censoring based on read quality and haplotype abundance consistent with 
prior studies.70,124,188  
In our longitudinal study of paired participant and mosquito P. falciparum 
infections, compared to people with symptomatic malaria infections, those with 
asymptomatic infections were more than twice as likely to successfully transmit P. 
falciparum to Anopheles mosquitoes. Future studies can investigate biological and 
epidemiological mechanisms by which symptomaticity influences transmission as well 
as estimate the feasibility and efficacy of targeting asymptomatic infections as a means 






Table 6.1. Comparison of pairings of participant and mosquito infections by symptomatic status 
 
Abbreviations: IQR, interquartile range; NE, not evaluated 
# The probability of transmission based on the time interval was set as 1 for all participant-mosquito pairings where the mosquito was 
collected within 7 days prior to or 14 days after the participant’s infection. All pairings outside of that time interval had a probability of 
transmission of 0. 
*The probability of transmission based on the pfcsp haplotype sharing and prevalence is shown for all pairings regardless on if they 
shared haplotypes or not.  
**The number of pfcsp haplotypes shared is shown for all pairs regardless on if they shared haplotypes or not.  
a Wilcoxon Rank Sum test with continuity correction and Bonferroni correction for repeated measures 







Participant-level covariates  
Parasite density (parasites/L), Median (IQR) 11.08 (0.96-251) 3229.46 (505-6581) <0.001a 
Age, N (%)   <0.001b 
    <5 years 326 (3.72) 112 (15.66)  
    5-15 years 1372 (45.55) 111 (15.52)  
    >15 years 1314 (43.63) 492 (68.81)  
Mosquito abundance, N (%)   <0.001b 
    Low 1564 (51.93) 227 (31.75)  
    High 1448 (48.07) 488 (68.25)  
Number of pfcsp haplotypes, Median (IQR) 3.00 (1.00-8.00) 2.00 (1.00-3.00) <0.001a 
Village, N (%)   <0.001b 
    Maruti 2267 (75.27) 411 (57.48)  
    Kinesamo 616 (20.45) 208 (29.09)  
    Sitabicha 129 (4.28) 96 (13.43)  
Participant-mosquito pair-level covariates  
Probability of transmission, Median (IQR)  
    Across all variables 0.05 (0.00-0.16) 0.00 (0.00-0.11) <0.001a 
        Time interval# 1.00 (1.00-1.00) 1.00 (1.00-1.00) NE 
        Distance interval 0.67 (0.54-0.84) 0.70 (0.53-0.80) 1.000a 
        pfcsp haplotype sharing and prevalence* 0.09 (0.00-0.24) 0.00 (0.00-0.15) <0.001a 
                For those that shared pfcsp haplotypes 0.20 (0.09-0.32) 0.19 (0.10-0.37) 1.000a 
Number pfcsp haplotypes shared, Median (IQR)** 1.00 (0.00-2.00) 0.00 (0.00-1.00) <0.001a 
                For those that shared pfcsp haplotypes 2.00 (1.00-3.00) 1.00 (1.00-1.00) <0.001a 







Figure 6.1. P. falciparum infections observed across study participants and 
female Anopheles mosquitoes across 14 months. 
Female Anopheline mosquitoes were captured weekly by vacuum aspiration and their 
abdomens were tested using real-time PCR for the presence (red) or absence (gray) of 
P. falciparum (Pf) parasites. Symptomatic malaria infections were captured by passive 
case detection with clinical symptoms and positive P. falciparum results by both RDT 
and real-time PCR (blue). The number of participants who had malaria-like symptoms 
and requested a symptomatic visit but did not have a confirmed symptomatic infection 
were also identified (grey). Asymptomatic malaria infections were captured by active 
case detection at monthly follow-up visits with participants and real-time PCR-positive 
for P. falciparum. These monthly visits were conducted in different weeks for each of the 
3 villages, with additional re-visits if needed to sample enrolled participants who were 
absent for the initial visit. Monthly counts of asymptomatic malaria infections (yellow) 






Figure 6.2. Distributions of pfcsp haplotypes across and within participants and 
mosquitoes. 
6.2A: Distribution of the 75 most common pfcsp haplotypes) in mosquitoes (red), 
symptomatic infections (blue), and asymptomatic infections (yellow), ordered vertically 
by the number in the asymptomatic infections. A full plot of all 229 pfcsp haplotypes 
across sample types is in the supplement (Figure S6.12). 6.2B: Multiplicity of infection 
(MOI) based on observed number unique pfcsp haplotypes in each mosquito abdomen 




Figure 6.3. Comparison of the proportion of infected mosquitoes harboring a 
matching pfcsp haplotype for participants with both asymptomatic and 
symptomatic infections. 
6.3A: Scatterplot of the proportion of pairings with a mosquito that shared a minimum of 
one haplotype for asymptomatic (y-axis) and symptomatic (x-axis) infections. Each dot 
is a participant who suffered at least one asymptomatic and symptomatic infection, and 
for participants with more than one of either type of infection, the plotted value is the 
median of proportions across infections within that type. Size of dots is relative to the 
total number of the participant’s infections. 6.3B: Odds ratios of the proportion of 
matched mosquitoes in a multi-level logistic regression model using the continuous 
coding of the proportion of participant-mosquito pairings that shared haplotypes for each 







Figure 6.4. Modeling approach to estimate the probability of a P. falciparum 
transmission event to mosquitoes using the pfcsp gene target. 
6.4A: Distribution of the interval in days between all possible pairings (N=159,285) of all 
infected participants and mosquito abdomens. Day 0 was set as the date of the 
mosquito infection, and therefore negative values indicate the mosquito was collected 
prior to the participant infection. The light green area indicates those pairings in which 
the mosquito was collected within 7 days prior to or 14 days after the participant’s 
infection. Subsequent analysis was restricted to these pairings. 6.4B: Distribution of the 
distance interval between all possible pairings of infected participants and mosquito 
abdomens. The light green area indicates those pairings within the same village and at 
a maximum distance of 3 kilometers, to which subsequent analysis was restricted. 
Across these pairings, a probability function was applied (S6.6 Fig) to upweight pairings 
with shorter distance intervals. The peaks result from differences in distance across the 
three villages. 6.4C: Distribution of the estimated probabilities of transmission as a 
function of the number of pfcsp haplotypes shared within the participant-mosquito pair. 
These probabilities were estimated by upweighting pairings which shared more 
haplotypes and which shared haplotypes that were rare across the entire study 
population. 6.4D: Distributions of final estimated probabilities of transmission events 
stratified by symptomatic status of the participant infection. Final probabilities were 
computed as the product of the individual probabilities based upon the time interval, 







Figure 6.5. Multi-level logistic regression results for the odds of a participant-to-
mosquito malaria transmission event from participants with asymptomatic 
compared to symptomatic infections using the pfcsp gene target. 
6.5A: Odds ratios (ORs) of the probability of malaria transmission events from infected 
participants to mosquitoes. ORs were computed using a multi-level logistic regression 
model with the probability of transmission outcome coded continuously. Values above 1 
indicate a factor that is associated with a greater likelihood of transmission of parasites 
to a mosquito, while values below 1 indicate a lesser probability. 6.5B: ORs of the 
probability of transmission from infected participants to mosquitoes were re-estimated 
using multi-level logistic regression models with the outcome coded dichotomously. 
Models were computed iteratively by dichotomizing the probability of transmission at 
increasing values from 0.00 to 0.55, thereby increasing the stringency of the definition of 
a transmission event. The dark yellow line indicates the OR at each dichotomized level 
of the probability outcome, and the shaded area indicates the 95% confidence interval 
around each OR. 6.5C: The contribution to the infectious reservoir was calculated using 
the odds of transmission to mosquitoes from participants with asymptomatic compared 






CHAPTER VII: CONCLUSIONS 
 
 
Summary of Findings 
 This dissertation study was motivated by the sustained high P. falciparum 
malaria burden in many parts of sub-Saharan Africa in spite of increased transmission 
reduction efforts. We aimed to better understand the natural history of asymptomatic 
malaria and its potential role as a reservoir for sustained transmission; to do this, we 
investigated asymptomatic malaria’s influence on attainment of future symptomatic 
infections at the individual and genomic levels as well as its transmission to mosquitoes. 
We hypothesized that prior asymptomatic infections would increase the short-term 
hazard of symptomatic infection, and similarly, new infections would increase the odds 
of developing symptomaticity. At the population level, we anticipated asymptomatic 
malaria would be a larger source of transmission to mosquitoes compared to 
symptomatic illness. These genomic, individual, and population-level effects were 
studied in a region in Western Kenya with high, perennial malaria transmission. 
Asymptomatic infections were common in our study site, highlighting the need to learn 
more about its influence on symptomaticity risk and its role as a reservoir.  
 The study used a longitudinal cohort of participants followed from June 2017 to 
November 2019 in Webuye, Kenya. Monthly, dried blood spots were collected from 
participants, and, weekly, mosquitoes collected from their households. We combined 
amplicon deep sequencing, probabilistic and multi-level modelling, and time-to-event 
92 
 
analysis methods to investigate the individual and genomic-level effects of 
asymptomatic infections acquired over time on symptomaticity as well as the 
population-level effects of asymptomatic malaria’s transmission to mosquitoes.   
At the individual level in aim 1A, we found, compared to being uninfected at 
monthly visits, asymptomatic infections greatly increased the short-term, 1-month 
hazard of symptomatic malaria, having a hazard 2.6 times that when uninfected; this 
association was similar when follow-up was expanded to 3 and 6 months but greatly 
weakened when following participants for 12 months or more.  
At the genomic level in aim 1B, we observed that, compared to infections with 
haplotypes a person had been infected with before, incident infections with only new 
haplotypes increased odds of symptomatic malaria over 3-fold; however, this increased 
risk of symptomatic disease with new parasite haplotypes was attenuated when new 
haplotypes were mixed with recurrent ones or when people with persistent infections 
acquired new or recurrent parasite haplotypes.  
 At the population level in aim 2, we identified asymptomatic infections as the 
major source of onward malaria transmission, with asymptomatic infections having 2.6 
times the odds of probable transmission to mosquitoes compared to symptomatic 
infections. Additionally, asymptomatic infections were the likely source of almost 95% of 
mosquito infections in the study site.  
 The dissertation findings suggest that, in high transmission areas, asymptomatic 
infections highly contribute to both future short-term symptomatic malaria risk as well as 
sustained malaria transmission. Taken together, this research provides a rationale for 
targeting asymptomatic infections for both medical and public health motives, as 
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reducing asymptomatic infections is expected to lessen the risk of symptomatic illness 
for individuals and create outsized transmission reduction for the population.  
Strengths and Limitations 
 Specific strengths and limitations of each aim are described below across five 
main topics inherent in epidemiology training: confounding, measurement, missingness, 
selection, and generalizability.  
Confounding  
 The minimally sufficient adjustment set of confounding covariates for each aim 
was chosen using a DAG analysis, with no unmeasured confounders identified. For 
causal inference analyses, there is a large assumption that there is no unmeasured 
confounding, and, thus, conditional exchangeability, comparing the exposure 
categories. In aim 1A, by allowing participant exposure to vary over time, we assumed 
exchangeability between the exposed and unexposed groups; approximately 94% of the 
study population changed exposure status at least once during follow-up, so lack of 
exchangeability between groups in our study population was not a large concern. In aim 
1B, all haplotype categories were observed across both asymptomatic and symptomatic 
infections, suggesting exchangeability across haplotype categories.  
Measurement 
In aim 1A, we used a qPCR assay with high sensitivity,129 but it is possible some 
infections were not detected. Pre-symptomatic infections could have also been 
misclassified as asymptomatic infections in aims 1A and 1B; sensitivity analyses were 
performed to detect how these pre-symptomatic infections influenced study results. In 
aim 1B, misclassification could have also occurred between recurrent and persistent 
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haplotypes; to minimize this risk, we excluded infections where participants had a 
symptomatic infection, were prescribed antimalarials, and had another infection with 
persistent haplotypes within 30 days of the initial infection.  
In aim 2, we had no direct measurement of gametocytes due to the method of 
sample collection and gDNA extraction; however, we adjusted models for asexual 
parasite density, which has been suggested as a proxy for gametocyte density.158 For 
aims 1B and 2, many infections in participants and mosquitoes had low parasite 
densities, which increases the risk of haplotype false discovery.124 To mitigate this risk, 
we enforced stringent haplotype censoring based on read quality and haplotype 
abundance consistent with prior studies.70,124,188 
Missingness 
Across all three aims, asymptomatic infections were only captured at monthly 
follow-up visits, missing asymptomatic infections that arose and cleared between visits. 
We did not observe malaria infections participants acquired prior to the study but 
approximated previous malaria exposure by including participant age in the models in 
aims 1A, 1B, and 2. Additionally, in regards to aim 1B, misclassifying haplotypes as new 
when they had been acquired prior to the study would have biased results towards the 
null.   
 In regards to aims 1B and 2, while amplicon deep sequencing was a sensitive 
method for identifying different malaria infections,110 it might not have captured all 
genetically distinct infections that occurred during the study. To account for this, we 
compared results across two unlinked parasite gene targets, pfama1 and pfcsp. Missing 
data bias due to sequencing failure was also investigated for aims 1B and 2, with there 
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being a statistically significant correlation between lower parasite density and 
sequencing failure; however, a DAG representing missingness due to sequencing 
failure indicated that restricting the data set to samples that passed sequencing was 
unlikely to produce missing data bias (Figure S6.4). As a precaution to account for 
lower parasite density samples potentially being biased towards sequencing failure and 
a form of missing at random bias, we included a covariate in our models for parasite 
density. 
In aim 2, we only measured human-to-mosquito malaria transmission directly 
within households, and could not capture events occurring in other settings. This 
limitation is mitigated by the known nocturnal feeding preference of the female 
Anopheles mosquitoes in this area.  
Selection 
Across all aims, participants were chosen using radial sampling of households 
across three villages with similar high malaria transmission. In aim 2, we may have 
under-detected asymptomatic infections and therefore over-represented symptomatic 
infections, owing either to the sparse monthly sampling for asymptomatic infections or 
the inability to capture transmission from symptomatic infections during their 
asymptomatic or pre-symptomatic phase. We expect that this would serve mainly to 
bias our analyses towards the null by providing relatively more opportunities for 
symptomatic infections to match to mosquitoes. Similarly, mosquito sampling was 
sparser than human sampling, which caused us to miss some transmission events and 




This dissertation study was based in a high malaria transmission region and 
included participants of all ages, and findings may be relevant to other areas of sub-
Saharan Africa with high P. falciparum prevalence. It is important to note, however, in 
aim 1A, that the Hernán et al. method has limited transportability to other study sites 
with different infection dynamics.109 Additionally, in aim 2, symptomatic infections were 
quickly diagnosed and treated with antimalarials under our protocol which likely reduced 
the duration of these infections and therefore limited their transmission potential. The 
access to diagnosis and treatment in our study is higher than is generally available 
across sub-Saharan Africa,145 though recent reports indicate gradual improvement in 
quality clinical management.187 Overall, this study demonstrates enhanced 
methodological approaches to study asymptomatic malaria at the genomic, individual, 
and population levels that could be applied to other study settings.  
Public Health Implications and Future Directions 
Broadly, our results highlight the major role asymptomatic P. falciparum plays in 
shaping malaria transmission dynamics in regions with high malaria prevalence. We 
found that asymptomatic malaria exposure over time increased the short-term hazard of 
symptomatic illness. We also observed an association between acquisition of new 
haplotypes in incident infections and increased odds of symptomatic disease, indicating 
the critical influence of parasite genetic diversity on symptomaticity. Additionally, these 
asymptomatic infections were large contributors to mosquito infection and onward 
malaria transmission.  
Given the detrimental individual- and population-level health effects of 
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asymptomatic P. falciparum in our study site, expanded interventions to reduce the 
asymptomatic reservoir in high transmission settings could be beneficial. Examples 
include increasing access to insecticide-treated bed nets, ramping up administration of 
endectocides like ivermectin,189 and expanding the use of targeted test and treat 
strategies for identifying and treating asymptomatic infections in addition to symptomatic 
ones.34 Treating asymptomatic infections could have detrimental effects, such as 
increased drug resistance and risk of symptomatic malaria post-treatment,18,190–194 
possibly by limiting exposure to prior diverse infections. Reduced exposure would 
increase the likelihood that incident infections are composed of new haplotypes and 
therefore likely to manifest symptoms. However, if reduced transmission is 
accompanied by reductions in parasite genetic diversity as has been reported in several 
settings,155,156 even with fewer prior infections the likelihood that a parasite will harbor 
recurrent haplotypes that attenuate symptoms would remain high. Precautions would 
still be needed, however, to limit drug resistance. 
Future research could expand upon our work in several ways. We urge more 
studies to incorporate frequent longitudinal sampling of asymptomatic infections in 
people of all ages to enhance knowledge of time-to-symptomatic malaria in adults. 
Future work could also explore at the immunological level how infection with new 
haplotypes changes the risk of symptomatic malaria compared to infection with 
recurrent or persistent haplotypes; we were the first study to differentiate between these 
two types of previously seen haplotypes and were unable to directly assess 
immunological markers. Finally, high malaria transmission settings like ours rely on 
usage of insecticide-treated bed nets, rapid diagnostics for malaria, and treatment with 
98 
 
artemisinin-based combination therapies for malaria control.34 The asymptomatic 
malaria burden has remained high in our study site despite adoption of all these 
methods, suggesting the need for enhanced interventions. Future studies could assess 
new ways to identify, treat, and reduce the asymptomatic malaria reservoir.   
Using innovative methodological approaches, we learned more about the natural 
history of asymptomatic malaria at the genomic, individual, and population levels. In our 
high malaria transmission study site, we found that asymptomatic P. falciparum 
infections increased the short-term hazard of symptomatic illness and served as the 
primary source of infections in mosquito vectors. Results provide a clear rationale to 











Supplementary Information for Chapter IV 
Alternative Models Comparing Asymptomatic Malaria Exposure and Resulting 
Symptomatic Illness 
 
 As an alternative approach to assess how asymptomatic infection versus no 
infection affected the likelihood of having a symptomatic malaria infection, a multi-level 
logistic regression model was ran controlling for age (categorized: <5 years, 5-15 years, 
>15 years), sex (categorized: male, female), and regular bed net usage (categorized: 
averages > 5 nights a week sleeping under a bed net – yes, no) and including a random 
intercept at the participant level. Results suggested that the 30-day odds of 
symptomatic malaria in participants with asymptomatic infections during monthly visits 
was 2.70 (95% confidence interval (CI): 2.09 to 3.49) times the odds of those that were 
uninfected at those visits.  
 For an additional approach, we also reran the frailty Cox proportional hazards 
model described in Equation 4.1 in the main text using a robust error estimator instead 
of random intercept to account for clustering at the participant-level. Results were 
similar to the original frailty model as well as the logistic regression, suggesting that 
people with asymptomatic infections had a hazard of symptomatic malaria 2.51 (95% 
CI: 1.89 to 3.34) times the hazard of people that were uninfected.  
Symptomatic Malaria Primary Case Definition Effect Measure Modification Results 
All effect measure modification results by age and sex are summarized in Table 
S4.4. Effect measure modification by age or sex was investigated for the 1-month effect 
of asymptomatic malaria exposure on the hazard of symptomatic illness. In the main 
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model, this relationship was not modified by age (p-value = 0.447 by log-likelihood ratio 
test): < 5 years [HR: 3.77, 95% CI: 2.02 to 7.04], 5-15 years [HR: 2.45, 95% CI: 1.79 to 
3.35], and > 15 years [HR: 2.55, 95% CI: 1.57 to 4.15]. In contrast, the relationship was 
modified by sex (p-value = 0.006 by log-likelihood ratio test), with females having a 
stronger short-term hazard of symptomatic malaria [HR: 3.71, 95% CI: 2.62 to 5.24] 
after asymptomatic malaria exposure compared to males [HR: 1.76, 95% CI: 1.24 to 
2.50] using the primary case definition for symptomatic malaria but not using the 
secondary stringent or permissive case definitions (Figure S4.2). In the pre-
symptomatic malaria, this relationship was not modified by age (p-value = 0.507 by log-
likelihood ratio test): < 5 years [HR: 2.85, 95% CI: 1.19 to 6.79], 5-15 years [HR: 1.61, 
95% CI: 1.05 to 2.46], and > 15 years [HR: 1.90, 95% CI: 0.93 to 3.86] or sex (p-value = 
0.094 by log-likelihood ratio test): males [HR: 1.24, 95% CI: 0.75 to 2.05] and females 
[HR: 2.34, 95% CI: 1.47 to 3.71]. In a post-treatment analysis assessing infections at 
least 14 days post-antimalarial treatment, the relationship between asymptomatic 
malaria exposure and the 1-month hazard of symptomatic illness was not modified by 
participant age (p-value = 0.864 by log-likelihood ratio test), with similar hazard ratios 
across age categories: < 5 years [HR: 2.06, 95% CI: 0.87 to 4.85], 5-15 years [HR: 2.61, 
95% CI: 1.68 to 4.06], and > 15 years [HR: 2.96, 95% CI: 1.09 to 8.04]. No effect 
measure modification was observed by participant sex (p-value = 0.416 by log-likelihood 
test): males [HR: 2.11, 95% CI: 1.27 to 3.51] and females [HR: 3.00, 95% CI: 1.77 to 
5.08]. 
 For the 3-month hazard of symptomatic malaria, effect measure modification was 
not observed by participant age (p-value = 0.128 by log-likelihood ratio test). Adjusted 3-
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month hazard ratios were similar across participant age categories: < 5 years [HR: 2.47, 
95% CI: 1.59 to 3.84], 5-15 years [HR: 1.49, 95 CI: 1.21 to 1.85], and > 15 years [HR: 
1.69, 95% CI: 1.23 to 2.32]. The 3-month hazard of symptomatic malaria was modified 
by sex (p-value = 0.009 by log-likelihood ratio test) with females [HR: 2.03, 95% CI: 1.62 
to 2.55] having a stronger relationship than males [HR: 1.29, 95% CI: 1.01 to 1.64]. In 
the pre-symptomatic analysis, effect measure modification by age was not observed (p-
value = 0.164 by log-likelihood ratio test): < 5 years [HR: 2.00, 95% CI: 1.20 to 3.34], 5-
15 years [HR: 1.16, 95% CI: 0.90 to 1.48], > 15 years [HR: 1.35, 95% CI: 0.94 to 1.93]. 
Modification by sex was not observed (p-value = 0.064 by log-likelihood ratio test): 
females [HR: 1.52, 95% CI: 1.18 to 1.97] and males [HR: 1.05, 95% CI: 0.79 to 1.39]. 
 For the 6-month hazard of symptomatic malaria, there was no effect measure 
modification by age (p-value = 0.197 by log-likelihood ratio test): < 5 years [HR: 1.94, 
95% CI: 1.34 to 2.80], 5-15 years [HR: 1.32, 95% CI: 1.11 to 1.57], > 15 years [95% CI: 
1.31, 95% CI: 1.01 to 1.70]. Modification was present by sex (p-value = 0.013 by log-
likelihood ratio test) with females [HR: 1.62, 95% CI: 1.35 to 1.94] having a stronger 
association than males [HR: 1.13, 95% CI: 0.93 to 1.39]. In the pre-symptomatic 
analysis, age did not appear to modify the relationship between asymptomatic malaria 
exposure and symptomatic illness (p-value = 0.210 by log-likelihood ratio test): < 5 
years [HR: 1.63, 95% CI: 1.08 to 2.46], 5-15 years [HR: 1.11, 95% CI: 0.92 to 1.34], and 
> 15 years [HR: 1.10, 95% CI: 0.83 to 1.46]. Slight modification was observed by sex (p-
value = 0.050 by log-likelihood ratio test): females [HR: 1.33, 95% CI: 1.09 to 1.62] and 
males [HR: 0.98, 95% CI: 0.78 to 1.22].  
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 For the 12-month hazard of symptomatic malaria, no effect measure modification 
by age was observed (p-value = 0.264 by log-likelihood ratio test). Age-stratified models 
could not be calculated due to data sparsity. Effect measure modification by sex was 
not observed (p-value = 0.122 by log-likelihood ratio test): females [HR: 1.21, 95% CI: 
1.05 to 1.41] and males [HR: 1.10, 95% CI: 0.86 to 1.19]. In the pre-symptomatic 
analysis, age did not modify the relationship between asymptomatic malaria exposure 
and the hazard of symptomatic malaria (p-value = 0.201 by log-likelihood ratio test): < 5 
years [HR: 1.24, 95% CI: 0.88 to 1.74], 5-15 years [HR: 1.00, 95% CI: 0.86 to 1.17], > 
15 years [HR: 0.85, 95% CI: 0.68 to 1.07]. No modification was seen by sex (p-value = 
0.364 by log-likelihood ratio test) with similar hazard ratios across females [HR: 1.04, 
95% CI: 0.88 to 1.22] and males [HR: 0.91, 95% CI: 0.77 to 1.09]. 
The effect of asymptomatic malaria infection versus no infection on the 29-month 
hazard of symptomatic malaria was modified by participant age (p-value < 0.001 by log-
likelihood ratio test) with the strongest association in children < 5 years [HR: 1.38, 95% 
CI: 1.05 to 1.81], second-strongest in children 5-15 years [HR: 1.16, 95% CI: 1.02 to 
1.32], and weakest in adults > 15 years [HR: 0.96, 95% CI: 0.81 to 1.13] (Figure S4.3). 
No effect measure modification was observed by sex (p-value = 0.378 by log-likelihood 
ratio test) with males [HR: 1.08, 95% CI: 0.94 to 1.24] and females [HR: 1.14, 95% CI: 
1.01 to 1.30] having similar hazard ratios for symptomatic malaria. In contrast to the 
main model results, the pre-symptomatic analysis model found no relationship between 
exposure to asymptomatic malaria compared to no infection and the hazard of 
symptomatic malaria [HR: 1.02, 95% CI: 0.92 to 1.12]. Effect measure modification by 
age was observed (p-value <0.001 by log-likelihood ratio test): < 5 years [HR: 1.23, 
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95% CI: 0.92 to 1.64], 5-15 years [HR: 1.06, 95% CI: 0.93 to 1.21], and >15 years [HR: 
0.88, 95% CI: 0.74 to 1.05. Effect measure modification by sex could not be assessed 
due to data sparsity. 
Pre-symptomatic Sensitivity Analysis Across Longer Follow-up Periods 
A pre-symptomatic analysis was conducted to assess potential bias caused by 
misclassifying pre-symptomatic infections as asymptomatic at monthly follow-up visits. 
Similar to the 1-month analysis, for the 3-month follow-up the pre-symptomatic analysis 
found an increased hazard of symptomatic malaria within 3 months when a participant 
had an asymptomatic infection compared to being uninfected [HR: 1.28, 95% CI: 1.06 to 
1.55]. In contrast to the main model results, there was no association between 
asymptomatic infections and the hazard of symptomatic malaria when expanding follow-
up to 6 [HR: 1.16, 95% CI: 1.00 to 1.34], 12 [HR: 0.98, 95% CI: 0.87 to 1.10], and 29 
[HR: 1.02, 95% CI: 0.92 to 1.12] months. Effect measure modification by age and sex in 
the subset analyses was similar to the full analyses and recorded in Table S4.4. 
Symptomatic Malaria Secondary Permissive Case Definition Results 
As a sensitivity analysis for defining symptomatic malaria, the 1-month and 29-
month analyses were repeated using a secondary (permissive) case definition for 
symptomatic malaria. The secondary permissive case definition defined a symptomatic 
infection as one where at a participant had at least one symptom consistent with malaria 
during a sick visit and was P. falciparum positive by real-time PCR (qPCR). Under this 
case definition, there was a total of 5380 monthly follow-up visits with 1837 (34.2%) of 
visits indicating asymptomatic malaria exposure. Using the secondary permissive case 
definition, a total of 409 symptomatic infections occurred. Participants had a median of 1 
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(IQR: 0, 2) symptomatic infections during follow-up. Median time to symptomatic malaria 
when exposed to asymptomatic infections (137, IQR: 41, 308) was lower than when 
unexposed (190, IQR: 80, 333) (Table S4.2).  
 For the 1-month effect of asymptomatic malaria exposure, a multivariate frailty 
Cox proportional hazards model observed that asymptomatic infection exposure 
increased the short-term hazard of symptomatic malaria [HR: 1.97, 95% CI: 1.63 to 
2.40] (Figure S4.2). This relationship was not modified by participant age (p-value = 
0.482 by log-likelihood ratio test): < 5 years [HR: 2.27, 95% CI: 1.37 to 3.74], 5-15 years 
[HR: 2.09, 95% CI: 1.58 to 2.77], and > 15 years [HR: 1.77, 95% CI: 1.29 to 2.44]. The 
relationship was also not modified by sex (p-value = 0.293 by log-likelihood ratio test) 
with males [1.73, 95% CI: 1.30 to 2.32] and females [HR: 2.18, 95% CI: 1.68 to 2.83] 
having similar hazard ratios for symptomatic malaria (Figure S4.2). 
Testing the 29-month effect of asymptomatic malaria exposure, a frailty Cox 
proportional hazards model controlling for age, sex, bed net usage, and village found 
that exposure to asymptomatic infections over time had no relationship with the long-
term hazard of symptomatic malaria compared to having no malaria infections [Hazard 
ratio (HR): 1.20, 95% CI: 1.11 to 1.31] (Figure S4.3). Effect measure modification of this 
relationship was not observed by participant age (p-value = 0.494 by log-likelihood ratio 
test) with the long-term hazard of symptomatic malaria similar among children < 5 years 
[HR: 1.14, 95% CI: 0.90 to 1.44], children 5-15 years [HR: 1.23, 95% CI: 1.09 to 1.38], 
and adults > 15 years [HR: 1.19, 95% CI: 1.04 to 1.36] (Figure S4.3). Effect measure 
modification was not observed by sex (p-value = 0.159 by log-likelihood ratio test) 
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comparing hazard ratios across males [HR: 1.12, 95% CI: 0.99 to 1.26] and females 
[HR: 1.26, 95% CI: 1.13 to 1.41] (Figure S4.3). 
Symptomatic Malaria Secondary Stringent Case Definition Results 
As an additional sensitivity analysis for defining symptomatic malaria, the 1-
month and 29-month analyses were repeated using a secondary (stringent) case 
definition for symptomatic malaria. The secondary stringent case definition defined a 
symptomatic infection as one where at a participant had a self-reported fever during a 
sick visit and was P. falciparum positive by both RDT and qPCR. Under this case 
definition, there was a total of 5374 monthly follow-up visits with 1848 (34.3%) of visits 
indicating asymptomatic malaria exposure. Using the secondary stringent case 
definition, a total of 215 symptomatic infections occurred. Participants had a median of 0 
(IQR: 0, 1) symptomatic infections during follow-up. Median time to symptomatic malaria 
when exposed to asymptomatic infections (203, IQR: 52, 429) was lower than when 
unexposed (232, IQR: 104, 403) (Table S4.3). Median follow-up time to symptomatic 
malaria was also shorter when participants were living in the village Maruti (Table S4.3).  
For the 1-month of asymptomatic malaria exposure, a multivariate frailty Cox 
proportional hazards model observed that asymptomatic infection exposure increased 
the short-term hazard of symptomatic malaria [HR: 2.76, 95% CI: 2.11 to 3.62] (Figure 
S4.2). This relationship was not modified by participant age (p-value = 0.438 by log-
likelihood ratio test): < 5 years [HR: 3.94, 95% CI: 2.09 to 7.43], 5-15 years [HR: 2.64, 
95% CI: 1.88 to 3.72], > 15 years [HR: 2.47, 95% CI: 1.36 to 4.49]. Sex did not modify 
this relationship either (p-value = 0.061 by log-likelihood ratio test): males [HR: 2.05, 
95% CI: 1.39 to 3.02] and females [HR: 3.60, 95% CI: 2.46 to 5.28] (Figure S4.2). 
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Testing the 29-month effect of asymptomatic malaria exposure, a frailty Cox 
proportional hazards model controlling for age, sex, bed net usage, and village found 
that exposure to asymptomatic infections over time did not affect the long-term hazard 
of symptomatic malaria compared to having no malaria infections [Hazard ratio (HR): 
1.02, 95% CI: 0.92 to 1.13] (Figure S4.3). This relationship was modified by participant 
age (p-value < 0.001 by log-likelihood ratio test) with the strongest association in 
children < 5 years [HR: 1.38, 95% CI: 1.05 to 1.81], second-strongest in children 5-15 
years [HR: 1.10, 95% CI: 0.96 to 1.25], and weakest in adults > 15 years [HR: 0.73, 
95% CI: 0.59 to 0.90] (Figure S4.3). Effect measure modification could not be assessed 














Take exposure status at 
baseline and apply it over 
the full follow-up period 
Can misclassify person-time if 
exposure frequently changes over 
time, as happens with the 
exposure in our study; this was 
commonly done in previous time to 
symptomatic malaria studies14–19,21–
23 
Allow participants to 
change exposure group 
over follow-up  
Exposure is reassessed for 
participants over time and 
summarized as the number 
of months exposed 
Can have issues with left 
truncation bias for exposures that 
began before the study, as 
occurred in our study where 
participants could have been 
infected with asymptomatic malaria 
at baseline 
Ever-never approach 
Classify participant as 
exposed if were ever 
exposed during follow-up 
period 
Many issues with misclassification 
and “look-back” bias; Buchwald et 
al.20 did a modified version of this 
where participants were classified 
as unexposed until an 
asymptomatic infection occurred 
then classified as exposed for the 
remaining period afterward 
Hernán et al. multiple 
month method109 
Modified version of 
intention-to-treat where 
each month was treated as 
a baseline for follow-up; 
The exposure status of 
each monthly visit was 
applied to the subsequent 
follow-up period 
Allows exposure to change over 
time with more precision than the 
typical intention-to-treat approach; 
produces effect estimate that is 
predictive of future risk regardless 
of prior exposure so not prone to 
left truncation bias; some 
misclassification bias still possible 
but less than alternative methods 
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Table S4.2. Covariate distribution across symptomatic events: secondary 
permissive case definition 
 
 
Abbreviations: IQR, interquartile range 
#Regular bed net usage was defined as a person averaging > 5 nights a week sleeping under a bed net. 
*Total person-months indicates the total number of monthly follow-up visits ending in a symptomatic 
infection or censoring. 
**Symptomatic infections were defined using the secondary permissive case definition where a participant 
was P. falciparum-positive by qPCR as well as had at least one symptom consistent with malaria during a 
sick visit. 
a Wilcoxon Rank Sum test with continuity correction and Bonferroni correction for repeated measures. 
















Main exposure    <0.001a 
    No infection 3537 (65.8) 2122 (67.0) 190 (80, 333)  
    Asymptomatic infection 1837 (34.2) 1044 (33.0) 137 (41, 308)  
Age    1.000b 
    < 5 years 806 (15.0) 419 (13.2) 182 (57, 345)  
    5-15 years 2280 (42.4) 1556 (49.1) 174 (64, 337)  
    > 15 years 2288 (42.6) 1191 (37.6) 169 (64, 310)  
Sex    0.133a 
    Male 2374 (44.2) 1468 (46.4) 186 (67, 349)  
    Female 3000 (55.8) 1698 (53.6) 163 (61, 308)  
Regular bed net usage#    1.000a 
    No 1445 (26.9) 876 (27.7) 179 (67, 342)  
    Yes 3929 (73.1) 2290 (72.3) 171 (63, 320)  
Village    1.000b 
    Kinesamo 1846 (34.4) 1073 (33.9) 181 (65, 319)  
    Maruti 1669 (31.1) 1013 (32.0) 159 (60, 314)  
    Sitabicha 1859 (34.6) 1080 (34.1) 182 (68, 348)  
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Table S4.3. Covariate distribution across symptomatic events: secondary 
stringent case definition 
 
 
Abbreviations: IQR, interquartile range 
#Regular bed net usage was defined as a person averaging > 5 nights a week sleeping under a bed net. 
*Total person-months indicates the total number of monthly follow-up visits ending in a symptomatic 
infection or censoring. 
**Symptomatic infections were defined using the secondary stringent case definition where a participant 
was P. falciparum-positive by both RDT and qPCR as well as had a self-reported fever during a sick visit. 
a Wilcoxon Rank Sum test with continuity correction and Bonferroni correction for repeated measures. 
















Main exposure    0.018a 
    No infection 3532 (65.7) 1311 (65.6) 232 (104, 403)  
    Asymptomatic infection 1848 (34.3) 687 (34.4) 203 (52, 429)  
Age    0.106b 
    < 5 years 812 (15.1) 329 (16.5) 226 (82, 435)  
    5-15 years 2286 (42.5) 1161 (58.1) 209 (78, 389)  
    > 15 years 2282 (42.4) 508 (25.4) 254 (103, 459)  
Sex    1.000a 
    Male 2355 (43.8) 983 (49.2) 236 (88, 436)  
    Female 3025 (56.2) 1015 (50.8) 210 (82, 398)  
Regular bed net usage#    1.000a 
    No 1427 (26.5) 645 (32.3) 210 (84, 380)  
    Yes 3953 (73.5) 1353 (67.7) 233 (86, 432)  
Village    0.032b 
    Kinesamo 1853 (34.4) 695 (34.8) 241 (94, 440)  
    Maruti 1680 (31.2) 643 (32.2) 186 (66, 376)  
    Sitabicha 1847 (34.3) 660 (33.0) 238 (91, 427)  
     
 
 
Table S4.4. Age- and sex-stratified hazard ratios of time to symptomatic malaria 
 
 
Abbreviations: CI, confidence interval; HR, adjusted hazard ratio 
*Not calculated due to data sparsity 
Statistically significant effect measure modification by the log-likelihood ratio test is bolded.  
Comparison 
Age 
HR (95% CI) 
 Sex 
HR (95% CI) 
<5 years 5-15 years >15 years 
 
Male Female 
1-month main  3.77 (2.02,7.04) 2.45 (1.79,3.35) 2.55 (1.57,4.15)  1.76 (1.24,2.50) 3.71 (2.62,5.24) 
1-month pre-symptomatic 2.85 (1.19,6.79) 1.61 (1.05,2.46) 1.90 (0.93,3.86)  1.24 (0.75,2.05) 2.34 (1.47,3.71) 
1-month post-treatment 2.06 (0.87,4.85) 2.61 (1.68,4.06) 2.96 (1.09,8.04)  2.11 (1.27,3.51) 3.00 (1.77,5.08) 
3-month main 2.47 (1.59,3.84) 1.49 (1.21,1.85) 1.69 (1.23,2.32)  1.29 (1.01,1.64) 2.03 (1.62,2.55) 
3-month pre-symptomatic 2.00 (1.20,3.34) 1.16 (0.90,1.48) 1.35 (0.94,1.93)  1.05 (0.79,1.39) 1.52 (1.18,1.97) 
6-month main 1.94 (1.34,2.80) 1.32 (1.11,1.57) 1.31 (1.01,1.70)  1.13 (0.93,1.39) 1.62 (1.35,1.94) 
6-month pre-symptomatic 1.63 (1.08,2.46) 1.11 (0.92,1.34) 1.10 (0.83,1.46)  0.98 (0.78,1.22) 1.33 (1.09,1.62) 
12-month main Not calculated* Not calculated* Not calculated*  1.10 (0.86,1.19) 1.21 (1.05,1.41) 
12-month pre-symptomatic 1.24 (0.88,1.74) 1.00 (0.86,1.17) 0.85 (0.68,1.07)  0.91 (0.77,1.09) 1.04 (0.88,1.22) 
29-month main 1.38 (1.05,1.81) 1.16 (1.02,1.32) 0.96 (0.81,1.13)  1.08 (0.94,1.24) 1.14 (1.01,1.30) 








Table S4.5. Covariate distribution across symptomatic events comparing main 
analysis and post-treatment analysis datasets 
 
 
#Regular bed net usage was a person averaging > 5 nights a week sleeping under a bed net. 
*Symptomatic infections were defined using the primary case definition where a participant was 
P. falciparum-positive by both RDT and qPCR as well as had at least one symptom consistent 
with malaria during a sick visit. 


















Main exposure   1.000 
    No infection 1580 (65.7) 570 (68.3) - 
    Asymptomatic infection 826 (34.3) 264 (31.7) - 
Age   <0.001 
    < 5 years 329 (13.7) 63 (7.6) - 
    5-15 years 1319 (54.8) 617 (74.0) - 
    > 15 years 758 (31.5) 154 (18.5) - 
Sex   0.004 
    Male 1190 (49.5) 348 (41.7) - 
    Female 1216 (50.5) 486 (58.3) - 
Regular bed net usage#   1.000 
    No 730 (30.3) 257 (30.8) - 
    Yes 1676 (69.7) 577 (69.2) - 
Village   0.350 
    Kinesamo 876 (36.4) 259 (31.1) - 
    Maruti 745 (31.0) 294 (35.3) - 
    Sitabicha 785 (32.6) 281 (33.7) - 
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Figure S4.1. DAG illustrating covariate relationships for the association between 
exposure to asymptomatic malaria versus no infection and time to symptomatic 
malaria infection. 
The shaded grey boxes represent the main exposure and main outcome. The boxes 








Figure S4.2. Frailty Cox proportional hazards model results comparing exposure 
to asymptomatic malaria infections versus no infection over time and 1-month 
hazard of symptomatic malaria across the three case definitions for symptomatic 
malaria: primary, secondary permissive, and secondary stringent. 
The main model controls for covariates participant age, sex, bed net usage, and village. 
The age-stratified model controls for covariates sex, bed net usage, and village. The 
sex-stratified model controls for participant age, bed net usage, and village. Statistically 







Figure S4.3. Frailty Cox proportional hazards model results comparing exposure 
to asymptomatic malaria infections versus no infection over time and 29-month 
hazard of symptomatic malaria across the three case definitions for symptomatic 
malaria: primary, secondary permissive, and secondary stringent. 
The main model controls for covariates participant age, sex, bed net usage, and village. 
The age-stratified model controls for covariates sex, bed net usage, and village. The 
sex-stratified model controls for participant age, bed net usage, and village. Statistically 







Supplementary Information for Chapter V 
Description of pfama1 Haplotype Results 
For pfama1, we identified 193 haplotypes across 611 asymptomatic and 113 
symptomatic infections in 204 participants. After censoring participant’s initial infections 
and infections occurring within 14 days of antimalarial treatment, we observed 154 
haplotypes in 430 asymptomatic and 72 symptomatic infections across 156 participants. 
Across all 502 infections, only new haplotypes were found in 194 infections, new and 
recurrent haplotypes observed in 91 infections, and only recurrent haplotypes identified 
in 60 infections (Figure S5.2). Persistent haplotypes were observed in 157 infections.  
Assessing the potential for pre-symptomatic infections, persistent pfama1 
haplotypes (N=31) were not as commonly found in symptomatic infections as new or 
recurrent haplotypes (N=41); however, symptomatic infections with persistent pfama1 
haplotypes had a statistically significant shorter time between their most recent infection 
and symptomatic malaria (p-value <0.001 by Kruskal-Wallis 2 test), with most infections 
occurring within 12 days (range: 2 to 63) when persistent haplotypes were present as 
opposed to 50 (range: 7 to 327) when they were not (Figure S5.3). 
We ran a multi-level logistic regression model on data restricted to only infections 
with new or recurrent pfama1 haplotypes and controlling for within-individual random 
effects, the number of previous infections, transmission season, and age. Compared to 
infections with only recurrent haplotypes, model results found that infections with only 
new haplotypes [odds ratio (OR): 2.20, 95% confidence interval (CI): 0.66 to 7.40] or 
both new and recurrent haplotypes [OR: 1.21, 95% CI: 0.26 to 5.65] had higher odds of 
symptomatic malaria (Figure S5.4). Results were not statistically significant. Comparing 
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multi-level logistic regression models with and without interaction term for age indicated 
that the model accounting for effect measure modification by age was not a statistically 
significant better fit (p-value = 0.410 by log-likelihood ratio test). Due to data sparsity, 
age-stratified models were not able to be compared to assess effect measure 
modification by age using pfama1 haplotypes.  
Persistent pfama1 haplotypes were identified in 157 infections categorized into: 
(i) only persistent (N=44); (ii) new and persistent (N=60); (iii) recurrent and persistent 
(N=21); and (iv) new, recurrent, and persistent (N=32). Across all four categories, the 
number of days since the previous infection ranged from 2 to 65, with most infections 
occurring within 28 days (Figure S5.5). No statistically significant differences were 
observed in the time since previous infection across haplotype categories (p-value = 
0.432 by Kruskal-Wallis 2 test). 
To test how presence of the persistent haplotypes affected the odds of 
developing a symptomatic compared to asymptomatic malaria infection, we ran a multi-
level logistic regression model adjusting for within-individual random effects, age, the 
number of prior malaria infections, and transmission season. After restricting the model 
to consecutive infections with persistent haplotypes occurring within 30 days, the model 
assessed 109 infections with new or persistent pfama1 haplotypes across 81 
asymptomatic and 28 symptomatic infections. Compared to infections with only 
persistent pfama1 haplotypes, infections with mixed types of haplotypes [OR: 0.24, 95% 
CI: 0.06 to 1.00] had lower odds of symptomatic malaria (Figure S5.6). Due to small 
sample sizes, age-stratified models and the log-likelihood ratio test were unable to be 
performed to assess effect measure modification.  
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Table S5.1. Distribution of symptomatic status across covariates for infections 
with pfama1 new and recurrent haplotypes 
 
Abbreviations: IQR, interquartile range; NE, not evaluated 
# The number of prior malaria infections a participant had was categorized into low versus high. 
Low indicated 3 infections or fewer during the study period. High represented more than 3 
infections during the study period.  
*Transmission season was categorized into low versus high based on the mosquito abundance 
across the study site and malaria seasonality. The low transmission season was when  50 
mosquitoes were collected in the two weeks prior. The high transmission season was when > 
50 mosquitoes were collected in the two weeks prior to the person’s infection.  
**Multiplicity of infection (MOI) was categorized into low versus high based on a functional form 
assessment. Low MOI was  2 haplotypes, whereas high MOI was > 2 haplotypes. 









Haplotype category, N (%)   0.230a 
    Only new 163 (53.6) 31 (75.6)  
    New and recurrent 85 (28.0) 6 (14.6)  
    Only recurrent 56 (18.4) 4 (9.8)  
Age, N (%)   0.097a 
     15 years 187 (60.5) 34 (82.9)  
    > 15 years 117 (38.5) 7 (17.1)  
Number of prior malaria infections#, N (%)   0.468a 
    Low 221 (72.7) 36 (87.8)  
    High 83 (27.3) 5 (12.2)  
Transmission season*, N (%)   0.302a 
    Low 196 (64.5) 19 (46.3)  
    High 108 (35.5) 22 (53.7)  
Multiplicity of infection**, N (%)   1.000a 
    Low 180 (59.2) 29 (70.7)  
    High 124 (40.8) 12 (29.3)  
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Table S5.2. Distribution of symptomatic status across covariates for consecutive 
infections with pfama1 persistent and new or recurrent haplotypes 
 
Abbreviations: IQR, interquartile range; NE, not evaluated 
# The number of prior malaria infections a participant had was categorized into low versus high. 
Low indicated 3 infections or fewer during the study period. High represented more than 3 
infections during the study period.  
*Transmission season was categorized into low versus high based on the mosquito abundance 
across the study site and malaria seasonality. The low transmission season was when  50 
mosquitoes were collected in the two weeks prior. The high transmission season was when > 
50 mosquitoes were collected in the two weeks prior to the person’s infection.  
**Multiplicity of infection (MOI) was categorized into low versus high based on a functional form 
assessment. Low MOI was  2 haplotypes, whereas high MOI was > 2 haplotypes. 










Haplotype category, N (%)   <0.001a 
    Mixed types of haplotypes 67 (82.7) 12 (42.9)  
    Only persistent haplotypes 14 (17.3) 16 (57.1)  
Age, N (%)   1.000a 
     15 years 58 (71.6) 21 (75.0)  
    > 15 years 23 (28.4) 7 (25.0)  
Number of prior malaria infections#, N (%)   0.249a 
    Low 44 (54.3) 22 (78.6)  
    High 37 (45.7) 6 (21.4)  
Transmission season*, N (%)   0.919a 
    Low 52 (64.2) 13 (46.4)  
    High 29 (35.8) 15 (53.6)  
Multiplicity of infection**, N (%)   0.006a 
    Low 27 (33.3) 20 (71.4)  
    High 54 (66.7) 8 (28.6)  
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Figure S5.1. DAG of relationship between malaria haplotype categories and a 
participant’s symptomatic status. 
The haplotype categories differed depending on if new haplotypes were being 
compared to recurrent or persistent haplotypes. The DAG indicated that participant age, 
number of prior malaria infections, malaria transmission season, and multiplicity of 







Figure S5.2. Venn diagram of pfama1 haplotype categories across all malaria 
infections. 
Each number indicates the number of infections that had haplotypes within each 







Figure S5.3. Comparison of time since previous infection for infection with or 
without persistent pfama1 haplotypes.  
Distribution of the number of days since previous infection for symptomatic malaria 
infection was stratified by whether or not the infection had persistent pfama1 haplotypes 





Figure S5.4. Odds of symptomatic malaria comparing infections with new versus 
recurrent pfama1 haplotypes. 
Multi-level logistic regression results for the odds of symptomatic malaria comparing (i) 
only new versus only recurrent (dark red) and (ii) new and recurrent versus only 
recurrent pfama1 haplotypes (light red). Odds ratios are represented by the dots with 







Figure S5.5. Distribution of days since previous infection for infections with 
persistent pfama1 haplotypes. 
Distribution of the number of days since previous infection for malaria infections with 
persistent pfama1 haplotypes. Infections were categorized into: (i) only persistent; (ii) 
new and persistent; (iii) recurrent and persistent; and (iv) new, recurrent, and persistent. 







Figure S5.6. Odds of symptomatic malaria comparing persistent infections with 
mixed types of pfama1 haplotypes versus only persistent haplotypes. 
Adjusted multi-level logistic regression results for the odds of symptomatic malaria 
comparing consecutive infections with mixed types of haplotypes versus only persistent 
haplotypes (dark blue). Odds ratios are represented by the dots with the lines indicating 







Supplementary Information for Chapter VI 
Additional Sample Processing Methodology 
Participant DBS samples and mosquito abdomens were shipped to Duke 
University in Durham, North Carolina, where they were processed to determine P. 
falciparum infection status and haplotypes. Mosquito parts were individually ground in 
1% Saponin using a micro tube homogenizer system fitted with a pestle, and the 
homogenate was transferred to unique wells of a deep 96-well plate. Single 6mm 
punches from the DBS were likewise distributed in deep well plates and genomic DNA 
was extracted from mosquito and DBS samples using a Chelex-100 protocol.128 As 
described in Taylor et al.,129 each sample was tested in duplicate for P. falciparum 
parasites using a duplex TaqMan real-time PCR assay targeting the P. falciparum 
pfr364 motif and the human -tubulin gene.  
P. falciparum positive DBS gDNA was prepared for genotyping based on qPCR 
Ct-values. Samples with Ct 25 to 30 were applied to Genomic DNA Clean & 
Concentrator-10 columns, and for samples with Ct >30, gDNA from a second punch of 
each identical DBS was added to the initial sample and the total applied to RNA Clean 
& Concentrator-5 columns. P. falciparum positive mosquito gDNA samples were applied 
to DNeasy PowerClean Pro Cleanup columns and the eluate concentrated by EtOH 
precipitation. 
Library preparation for sequencing followed methods described in Nelson et al.148 
but with the following exceptions. PCR1 reactions contained 300 nM of each primer and 
2 L of template gDNA when DBS sample Ct was < 25, 5 L when Ct 25 to 30, 9 L 
when Ct > 30, and 7 L for mosquito gDNA. PCR2 reactions contained 2 L template 
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when DBS sample Ct < 25, 9 L when Ct  25, and 3 L for mosquito template. Dual-
indexed libraries were prepared for the polymorphic P. falciparum parasite gene targets 
encoding apical membrane antigen-1 (pfama1) and circumsporozoite protein (pfcsp), 
then pooled and sequenced on an Illumina MiSeq platform.117  
Additional Haplotype Calling Information for Samples for pfama1 and pfcsp 
pfama1 and pfcsp haplotypes were called using the amplicon deep sequencing 
reads. As in Nelson et al.,148 CutAdapt, Trimmomatic, and BBmap were used to trim 
pfama1 and pfcsp primers and adapters, quality filter reads with an average Phred 
Quality Score < 15 over a sliding window of 4 nucleotides, remove reads less than 80 
nucleotides long, and map sample reads to the 3D7 reference sequences for pfama1 
and pfcsp to differentiate between the two gene targets.118–120,148 Quality-filtered reads 
were input into the R (version 3.6.1) package DADA2 (version 1.8) to join paired-end 
reads, perform an additional quality filter based on modeled error frequency, call 
haplotypes, and remove chimeras.123,126 This process outputted haplotypes (distinct 
sequences of the pfama1 or pfcsp gene target) to be used as a measure of parasite 
genetic diversity. Because sequencing low parasite densities has been associated with 
an increased risk of haplotype false discovery,124 haplotypes were further filtered in 
order to mitigate the risk of false discovery by removing haplotypes from a sample that 
met any of the following criteria: (i) supported by < 250 reads within the sample; (ii) 
supported by < 3% of the sample’s total read depth; (iii) deviation from the expected 
nucleotide length of 300 for pfama1 or 288 for pfcsp; or (iv) a minority haplotype 
distinguished by a one single-nucleotide polymorphism (SNP) difference from another 
haplotype within the sample that had a read depth > 8 times the read depth of the 
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minority haplotype.124 Finally, we removed haplotypes from the overall population if 
each haplotype was defined by a single variant position that was only variable within 
that haplotype. 
We defined censoring criteria empirically by analyzing sequences of pfama1 and 
pfcsp obtained from controlled mixtures of P. falciparum strains 3D7, V1/S, 7g8, Dd2, 
and FCR3. The figure and table show results for the pfcsp region sequenced (Figure 
S6.1). P. falciparum V1/S and Dd2 strains were identical within the pfcsp region 
sequenced, so results are presented with the reads combined. To develop haplotype 
censoring criteria, the controls were sequenced in differing proportions (control mixtures 
C1-C6). After quality-filtering reads and applying the haplotype censoring criteria, the 
final percentage of reads of each strain was similar to what was expected from the 
control mixtures, as indicated in the figure and table. Because the censoring criteria 
filtered out reads that were present in < 3% of the sample’s total reads, the 3D7 and 7g8 
controls were filtered out in control mixture 6. Similar results were produced for pfama1.  
Comparison of Target Variant Positions with Prior Studies 
Across all samples, we compared the variant positions that we identified in the 
sequenced fragments of pfcsp and pfama1 with those identified in prior studies. To do 
so, we compiled variant positions in these fragments from PlasmoDB (accessed August 
1, 2019),163 the Pf3k database (accessed July 30, 2019),164 as well as an external data 
set (Neafsey et al.).162 For the latter, we downloaded raw sequencing reads and 
processed these with the haplotype inference criteria described above (Figure S6.2).162 
Through these searches, the number of variant positions in our sequenced fragment of 
pfcsp was 30 in PlasmoDB, 44 in Pf3k, and 39 in Neafsey et al.162–164 Overall, these 
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databases yielded a total of 57 variant positions, and 37 of these were among the 72 
nucleotide positions that we identified in our sequences.  
Haplotype Distributions Between Sample Types  
Because low parasite density samples were sequenced and strict filtering criteria 
were used, some samples failed sequencing and were not genotyped for pfcsp or 
pfama1. A total of 1242 samples were sequenced across 902 asymptomatic participant 
infections, 137 symptomatic participant infections, and 203 mosquito abdomens. After 
censoring criteria was applied, we identified pfcsp haplotypes in 185 mosquito 
abdomens, 733 asymptomatic infections, and 128 symptomatic infections (Figure 
S6.3). For pfama1, we identified haplotypes in 177 mosquito abdomens, 611 
asymptomatic participants, and 113 symptomatic participants. Based on these numbers, 
pfcsp had a sequencing failure rate of 196/1242 (15.78%) and pfama1 had a 
sequencing failure rate of 341/1242 (27.46%). Using the Wilcoxon Rank Sum test with 
continuity correction, there was a statistically significant correlation between parasite 
density and sequencing failure for pfcsp (p-value < 0.001) and pfama1 (p-value < 
0.001), with more sequencing failures for pfama1 than pfcsp. While there were 
statistically significant differences between parasite density and the likelihood of 
sequencing failure, a DAG representing missingness due to sequencing failure 
indicated that restricting the data set to samples that passed sequencing was unlikely to 
produce missing data bias (Figure S6.4); however, as a precaution to account for lower 
parasite density samples potentially being biased towards sequencing failure and a form 
of missing at random bias, we included a covariate in our models for parasite density.  
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Inferred pfama1 Haplotypes Across Samples 
For pfama1, 348 unique haplotypes were identified across 177 mosquito 
abdomens, 611 asymptomatic participants, and 113 symptomatic participants. 
Haplotypes produced from pfama1 had a median MOI of 7 for mosquito abdomens, 1 
for symptomatically-infected participants, and 2 for asymptomatically-infected 
participants.  
Functional Form Assessment for Continuous Variables 
A functional form assessment was conducted for continuous variables included in 
the models: parasite density in the participant samples, participant age at study 
enrollment, and mosquito abundance. The functional form assessment indicated that 
the optimal coding for parasite density was linear and rescaled to have a mean value of 
0.0 due to its interpretability and similar functional form (Table S6.3). For participant 
age, the categorical coding (categorized: <5 years, 5-15 years, >15 years) was the best 
choice, because it had the lowest Akaike information criteria (AIC) value, fit the 
functional form, and was a commonly used coding of age in malaria literature (Table 
S6.4). For mosquito abundance, a binary coding was chosen (expressed as the total 
number of female Anopheles mosquitoes collected within the week following the 
participant infection stratified at <75 mosquitoes or 75 mosquitoes), because that 
functional form had the lowest AIC, was easily interpretable, and had a similar functional 
form to the variable (Table S6.5).  
Within-participant Modeling of Transmissibility for pfama1 
Using the pfama1 haplotypes shared as a proxy for transmission, we selected 56 
participants who suffered at least one asymptomatic and one symptomatic infection that 
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passed genotyping for pfama1. The participants had multiple infections matched with 
mosquitoes consisting of 1197 participant-mosquito pairs. Mosquitoes were collected 
between 7 days before and 14 days after the participant infection and were within 3 
kilometers of the participant’s household. Asymptomatic infections (Median: 0.34) had a 
higher median proportion of pairings that shared at least one pfama1 haplotype with a 
mosquito compared to symptomatic infections (Median: 0.25) across the participants 
(Figure S6.13). In a multi-level logistic regression model controlling for parasite density 
and mosquito abundance, compared to symptomatic infections, asymptomatic infections 
had higher odds of sharing parasite haplotypes with infected mosquitoes [OR: 1.30, 
95% CI: 0.63 to 2.69] (Figure S6.14). 
Probabilistic Modeling of Transmission Across All Participants for pfama1 
For a more comprehensive analysis of all participants, we conducted an 
additional analysis of transmissibility using a probabilistic modelling framework. After 
applying time and distance constraints to participant-mosquito pairings, the final pfama1 
analysis data set consisted of 3160 observations of participant-mosquito pairs found 
across 178 participants, 172 mosquitoes, and 36 households. 2537 pairs had a 
participant with an asymptomatic infection and 623 pairs had a participant with a 
symptomatic infection. The overall probability of transmission outcome measure, 
𝑃(𝑇𝐸𝑎𝑙𝑙), ranged from 0.00 to 0.99 with a median of 0.00. Using the continuous coding 
of 𝑃(𝑇𝐸𝑎𝑙𝑙) and controlling for confounding covariates: parasite density in participant 
samples in parasites/L, participant age, mosquito abundance, and village, we found 
that over 14 months participants with asymptomatic infections had an odds of 
participant-to-mosquito malaria transmission that was 1.22 (95% CI: 0.82 to 1.82) times 
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the odds of transmission for participants with symptomatic infections (Figure S6.15).   
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Table S6.1. Comparison of participant-mosquito pairs among 65 participants 
included in within-participant modeling to full data set of all participants 
 
 Analysis  
data set 
 65 participants 
(1565 pairings) 
Full  




Participant-level covariates  
Parasite density (parasites/L),  
     Median (IQR) 
290.55 (3654.96) 43.49 (731.76) <0.001a 
Age, N (%)   <0.001b 
<5 years 179 (11.44) 438 (11.75)  
5-15 years 1105 (70.61) 1806 (48.46)  
>15 years 281 (17.96) 1483 (39.79)  
Number of pfcsp haplotypes,  
     Median (IQR) 
1.00 (2.00) 3.00 (6.00) 0.211a 
Number of infections per    
     participant, Median (IQR)   
3.00 (2.00) 2.00 (3.00) <0.001a 
    
 
Abbreviations: IQR, interquartile range 
a Wilcoxon Rank Sum test with continuity correction and Bonferroni correction for repeated 
measures 
b Pearson’s 2 test with Bonferroni correction for repeated measures  
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Table S6.2. Differences between participant-mosquito pairs that were excluded 









Parasite density (parasites/L), Median (IQR) 6.73 (166.45)  1,545.74 (6,370.95) 
Age, N (%)   
    <5 years 12,994 (9.80) 3,033 (13.21) 
    5-15 years 68,061 (51.33) 14,493 (63.11) 
    >15 years 51,538 (38.87) 5,439 (23.68) 
Mosquito abundance, N (%)   
    Low 115,911 (87.42) 15,128 (65.87) 
    High 16,682 (12.58) 7,837 (34.13) 
Number of pfcsp haplotypes, Median (IQR) 3.00 (5.00) 1.00 (2.00) 
Village, N (%)   
    Maruti 45,463 (34.29) 7,544 (32.85) 
    Kinesamo 37,124 (28.00) 6,267 (27.29) 
    Sitabicha 50,006 (37.71) 9,154 (39.86) 
Participant-mosquito pair-level covariates 
Probability of transmission, Median (IQR) 
    Across all variables# 0.00 (0.00) 0.00 (0.00) 
        Time interval 0.00 (0.00) 0.00 (0.00) 
        Distance interval 0.00 (0.51) 0.00 (0.47) 
        pfcsp haplotype sharing and prevalence* 0.09 (0.24) 0.00 (0.17) 
                For those that shared pfcsp haplotypes 0.20 (0.19) 0.20 (0.23) 
Number pfcsp haplotypes shared, Median (IQR)** 1.00 (2.00) 0.00 (1.00) 
                For those that shared pfcsp haplotypes 2.00 (2.00) 1.00 (0.00) 
   
 
Abbreviations: IQR, interquartile range 
# The probability of transmission across all variables was 0.00 because the participant-mosquito 
pairs were not within the distance and time restraints to be a likely participant-to-mosquito 
transmission.  
*The probability of transmission based on the pfcsp haplotype sharing and prevalence is shown 
for all pairings regardless on if they shared haplotypes or not.  
**The number of pfcsp haplotypes shared is shown for all pairs regardless on if they shared 




Table S6.3. Results of multi-level logistic regression models of probability of a 
transmission event using different functional forms of the P. falciparum parasite 
density in humans 
 




Linear   -601.0 1210.0 
   Parasite density 1.13 1.07   
     
Quadratic   -599.3 1208.7 
   Parasite density 0.70 1.34   
   Parasite density squared 1.08 1.04   
     
Cubic   -599.3 1210.6 
   Parasite density 0.75 1.48   
   Parasite density squared 1.03 1.21   
   Parasite density cubed 1.01 1.02   
     
Binary   0598.3 1204.7 
  <100 p/L (under cRDT detection) Ref Ref   
  100 p/L (over cRDT detection) 0.60 1.20   
     
Categorical   -596.0 1203.9 
  < 1.93 p/L Ref Ref   
   1.93 and < 51.64 p/L 1.34 1.25   
   51.64 and 773.53 p/L 






     
Natural Log   -600.1 1208.2 
   Parasite density ln 0.95 1.03   
     
 
Abbreviations: SE, standard error; AIC, Akaike information criteria; cRDT, conventional rapid 
diagnostic test  
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Table S6.4. Results of multi-level logistic regression models of probability of a 
transmission event using different functional forms of participant age 
 




Linear   -602.2 1212.5 
   Age 0.94 1.09   
     
Quadratic   -602.2 1214.5 
   Age 0.92 1.16   
   Age squared 1.01 1.08   
     
Cubic   -599.5 1211.1 
   Age 0.86 1.17   
   Age squared 0.69 1.20   
   Age cubed 1.14 1.06   
     
Categorical   -600.2 1210.5 
  <5 years Ref Ref   
  5-15 years 1.59 1.37   
  >15 years 1.14 1.39   
     
Natural Log   -602.5 1212.9 
   Age ln 1.01 1.10   
     
 
Abbreviations: SE, standard error; AIC, Akaike information criteria  
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Table S6.5. Results of multi-level logistic regression models of probability of a 
transmission event using different functional forms of the total number of female 
Anopheles mosquitoes collected within one week following participant infection 
 




Linear   -602.0 1211.9 
   Mosquito abundance 1.09 1.09   
     
Quadratic   -601.9 1213.8 
   Mosquito abundance 1.09 1.09   
   Mosquito abundance squared 1.04 1.09   
     
Cubic   -600.8 1213.6 
   Mosquito abundance 1.30 1.16   
   Mosquito abundance squared 1.08 1.10   
   Mosquito abundance cubed 0.92 1.06   
     
Binary     
  <75 mosquitoes Ref Ref -601.9 1211.7 
  75-147 mosquitoes 1.21 1.19   
     
Natural Log   -602.2 1212.5 
   Mosquito abundance ln 1.09 1.14   
     
 
Abbreviations: SE, standard error; AIC, Akaike information criteria   
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Figure S6.1. Expected and observed pfcsp haplotype frequencies in control 
mixtures of genomic DNA from P. falciparum reference lines. 
Expected strain mixtures were based on the input amounts of genomic DNA of each 
reference parasite strain. Strains V1/S and Dd2 share identical pfcsp haplotypes and 
therefore could not be resolved. Haplotypes in “C6” that mapped to 3D7 and 7g8 were 
censored because they were present in  3% in the overall read yield for that template. 






Figure S6.2. Comparison of overlap in the variant nucleotide positions within the 
sequenced pfcsp fragment identified in our study and in prior studies. 
The total number of variant nucleotide positions for each set was: Neafsey et al. = 39, 






Figure S6.3. Sample processing flow-diagram from original samples to censored, 
high-quality haplotypes. 
The number of samples and reads returned from each step of sample processing is 






Figure S6.4. DAG investigating potential for missing data bias in samples that 
failed sequencing. 







Figure S6.5. Probability of transmission over time. 
The probability of transmission over time [𝑃(𝑇𝐸𝑡)] distribution had a flat, high probability 
of transmission from -14 to 7 days to allow for each participant sample to have the same 
number of mosquito collections and the same probability of transmission within the time 
range. The distribution was restricted to only allow a transmission event to occur when a 
mosquito was collected within 14 days (i.e. -14 days) after the participant infection or 7 
(i.e. +7 days) days prior to the participant infection. Any participant-mosquito pair within 






Figure S6.6. Sensitivity analysis for probability of transmission over time. 
A sensitivity analysis was done to comparing different time windows for the probability 
of transmission over time [𝑃(𝑇𝐸𝑡)] and the effect on the relationship observed. The 
distribution was restricted to only allow a transmission event to occur when a mosquito 
was collected within 30 to 14 days (i.e. -30 to -14 days) after the participant infection or 
7 (i.e. +7 days) days prior to the participant infection. The multi-level logistic regression 
model was reran comparing the probability of transmission to mosquitoes across 
participants with asymptomatic compared to symptomatic infections using each time 
window. Each time window is shown on the y-axis and the associated odds ratio for 






Figure S6.7. Probability of transmission over distance. 
The distribution of the probability of transmission over distance [𝑃(𝑇𝐸𝑑)] decreased to a 
low probability of transmission as the distance between the participant infection and 
mosquito collection increased. At any distance greater than 3 kilometers, estimated 
𝑃(𝑇𝐸𝑑) = 0, allowing transmission events to occur across households but not villages. 
The curve stops at 0.56 kilometers, because no participants and mosquitoes were 






Figure S6.8. Sensitivity analysis for probability of transmission over distance. 
A sensitivity analysis was done to comparing different distance cutoffs for the probability 
of transmission and the effect on the relationship observed. The multi-level logistic 
regression model was reran comparing the probability of transmission to mosquitoes 
across participants with asymptomatic compared to symptomatic infections using each 
distance cutoff. Each maximum distance cutoff is shown on the y-axis and the 
associated odds ratio for transmission to mosquitoes on the x-axis. The pfcsp 






Figure S6.9. Number of shared pfcsp haplotypes between participants and 
mosquitoes at < 3 kilometers and  3 kilometers. 
The number of pfcsp haplotype shared between specimens collected at a distance < 3 
kilometers and  3 kilometers was compared.  
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Figure S6.10. Sensitivity analysis for probability of transmission over haplotypes. 
A sensitivity analysis was done using a different coding for the 𝑃(𝑇𝐸ℎ) term where it was 
no longer calculated separately for pfama1 and pfcsp but instead calculated as a 
combined value using both pfama1 and pfcsp haplotypes. The multi-level logistic 
regression model was reran comparing the probability of transmission to mosquitoes 






Figure S6.11. DAG of causal relationship between a participant’s symptomatic 
status and probability of a participant-to-mosquito transmission event.  
The DAG identified four confounding covariates that needed to be controlled for in 
assessing the effect of participants’ malaria symptomatic status on the probability of a 
participant-to-mosquito transmission event: age, parasite density in the participant 
samples in parasites/L, total number of female Anopheles mosquitoes collected within 
the week following the participant infection, and multiplicity of infection (MOI) in 





Figure S6.12. Haplotype distribution across sample types for pfcsp.  
The full distribution of pfcsp haplotypes across mosquitoes, asymptomatic infections, 
and symptomatic infections is shown here. This plot shows all pfcsp haplotypes 






Figure S6.13. Comparison of likelihood of transmission to mosquitoes for 
participants with both asymptomatic and symptomatic infections using the 
pfama1 gene target.  
For each participant (N=56), the median proportion of pairings with a mosquito that 
shared a minimum of one haplotype was calculated for asymptomatic and symptomatic 
infections to represent the average likelihood of transmission to a mosquito. Using the 
pfama1 gene target, asymptomatic infections had a higher median likelihood of 
transmission, as indicated by the higher number of dots to the left of the dotted diagonal 






Figure S6.14. Comparison of likelihood of transmission to mosquitoes for 
participants with both asymptomatic and symptomatic infections using the 
pfama1 gene target.  
We ran a multi-level logistic regression using the continuous coding of the proportion of 
participant-mosquito pairings that shared at least one pfama1 haplotype for each 
infection. The model controlled for covariates: parasite density in the participant 
samples in parasites/L (linear) and the mosquito abundance (binary: <75 mosquitoes, 
75 mosquitoes). Model results suggested higher odds of asymptomatic compared to 







Figure S6.15. Multi-level logistic regression results for odds of a participant-to-
mosquito malaria transmission from participants with asymptomatic compared to 
symptomatic infections using the pfama1 malaria gene target.  
We ran a multi-level logistic regression using the continuous coding of 𝑃(𝑇𝐸𝑎𝑙𝑙) and 
pfama1 haplotypes. The model controlled for covariates: parasite density in the 
participant samples in parasites/L (linear), age (categorized: <5 years, 5-15 years, >15 
years), the mosquito abundance (binary: <75 mosquitoes, 75 mosquitoes), and village. 
Model results suggested higher odds of asymptomatic compared to symptomatic 
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